Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP)
Collaborative research agreement; use of Abgenix¿s XenoMouse technology to generate fully human monoclonal antibodies to an undisclosed target antigen of Schering-Plough¿s
ND
Schering-Plough has option to enter research and license agreement under which Abgenix would get additional research and milestone payments as well as royalties (2/98)
Acacia Biosciences Inc.*
Bristol-Myers Squibb Co. (NYSE:BMY)
Compound profiling agreement; use of Acacia¿s Genome Reporter Matrix to profile small molecules against multiple disease pathways (identifies changes in gene expression in presence of drug)
ND
Bristol-Myers licensed technology and will make upfront payment for technology evaluation on a limited number of potential therapeutic compounds; further details ND (4/98)
Advanced Polymer Systems Inc.
Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)
Agreement to use Advanced Polymer¿s Microsponge system to develop a topical formulation of one of Pharmacia & Upjohn¿s therapeutics
ND
Pharmacia & Upjohn will fund all product development, conduct clinical trials and commercialize product worldwide; Advanced Polymer gets R&D funds, license fees, milestones and royalties (1/98)
Affymetrix Inc.
Beckman Coulter Inc. (NYSE:BEC)
Series of agreements to commercialize DNA probe arrays (including GeneChip) under patents owned by, or licensed to, the 2 parties
ND
Companies will cooperate in developing and commercializing DNA arrays and related instrumentation for research and diagnostics markets; companies may provide access to 3rd parties (8/98)
Affymetrix Inc.
Eli Lilly and Co. (NYSE:LLY)
EasyAccess agreement; GeneChip arrays, instrumentation and software for monitoring of gene expression
ND
3-year agreement; Lilly gets broad access to technology for use in its R&D programs; Lilly gets volume discount (9/98)
Affymetrix Inc.
Roche Molecular Systems Inc. (member of the Roche Group; Switzerland)
Joint development of diagnostic tests that combine Affymetrix¿s GeneChip DNA probe array technology with Roche¿s PCR gene amplification technology; initial focus will be diagnostic kits for testing HIV drug resistance as well as p53 gene assays for cancer staging
ND
Affymetrix will manufacture GeneChip probe arrays for both R&D and commercial phases of collaboration; Roche Molecular responsible for worldwide clinical development, regulatory approvals and marketing; Roche Molecular will develop instrumentation to support higher-throughput use of GeneChip products; Affymetrix will sell GeneChip arrays to Roche Molecular; companies will share equally a defined percentage of sales (4/98)
Agouron Pharmaceuticals Inc.
Japan Energy Corp. (Japan)
License agreement on Japan Energy¿s HIV protease inhibitor JE-2147 (especially for treating drug-resistant HIV)
$26M
Agouron gets exclusive rights to develop and commercialize drug in North America, Europe and elsewhere; Japan Energy retains rights in Japan, Korea and Taiwan; Japan Energy gets $26M in fees, including $6M initial license fee, plus royalties (6/98)
Agouron Pharmaceuticals Inc.
Shionogi & Co. Ltd. (Japan)
License agreement on Shionogi¿s 2nd-generation non-nucleoside HIV reverse transcriptase inhibitor S-1153 (especially for treating drug-resistant HIV)
$40M
Agouron gets exclusive rights to develop and commercialize drug in North America, Europe and elsewhere; Shionogi retains rights in Japan, Korea and Taiwan; Shionogi gets $40M in fees, including $10M initial license fee, plus royalties (6/98)
Alkermes Inc.
The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE: JNJ)
Agreement to develop injectable sustained-release formulation of erythropoietin via Alkermes¿ ProLease drug delivery technology; product for use in non-dialysis indications to restore blood cell levels in kidney patients
$30M
Alkermes gets $30M in development funds and milestones; Johnson & Johnson gets worldwide commercial rights; Alkermes gets milestones; Alkermes will manufacture commercial product; Johnson & Johnson will conduct clinical trials and get regulatory approvals (1/98)
Allelix Neuroscience Inc. (subsidiary of Allelix Biopharmaceuticals Inc.; Canada)
Janssen Pharmaceutica NV (Belgium; unit of Johnson & Johnson; NYSE:JNJ)
Research collaboration; use of Allelix¿s glycine re-uptake inhibitor technology (targets GlyT-1 gene) to develop drugs for neuropsychiatric disorders, especially schizophrenia
$6M (equity; % ND)
Allelix gets US$4M upfront, US$2M as cash license fee, research funds for 2 years, milestones and royalties; Johnson & Johnson Development Corp. will buy US$2M in convertible preferred stock (already owns 1.6% stake prior to this); Janssen has option to extend agreement; Janssen has worldwide marketing rights but Allelix gets option to co-promote in Canada (prices converted at a rate of C$1.55/US$1) (11/98)
Alza Corp.
Janssen Pharmaceutica NV (Belgium; unit of Johnson & Johnson; NYSE: JNJ)
Collaborative agreement to use Alza¿s E-Trans drug delivery technology (uses electric current to administer drug through the skin) with a fentanyl drug product for treating chronic pain
ND
Alza will fund product development for next 2 years; Janssen has limited option to fund development after that point; if it exercises option, Janssen will market product and Alza will share profits in U.S. and get royalties elsewhere; Alza has right to co-promote in U.S.; if Janssen does not exercise option, Alza retains all rights to develop and commercialize product worldwide (1/98)
Amrad Corp. (ASX:AML; Australia)
SmithKline Beecham plc (NYSE:SBH; U.K.)
Agreement to develop Amrad¿s vaccine for rotavirus infection (causes acute gastroenteritis in children)
ND
SmithKline has option to license vaccine pending successful completion of current clinical trial; if it exercises option, SmithKline will take over further product development and commercialize it worldwide; Amrad gets milestones and royalties (4/98)
Angiotech Pharmaceuticals Inc. (Canada)
C.R. Bard Inc. (NYSE:BCR)
License and development agreement; use of Angiotech¿s paclitaxel and related compounds for perivascular treatment of restenosis associated with vascular surgery
$19.4M
Angiotech gets total of US$19.4M in upfront license fees and milestones, plus royalties; both companies will fund product development; Bard and its subsidiary IMPRA Inc. get exclusive worldwide license (prices converted at rate of C$1.55/US$1) (12/98)
Antigenics LLC*
Sigma-Tau (Italy)
Collaboration; clinical trials on Antigenics¿ heat shock protein vaccines (HSPPC-96 is in Phase II trial for melanoma and colorectal cancer)
ND
Sigma-Tau will conduct clinical trials in Italy and will provide logistical and financial support; further details ND (10/98)
Aphton Corp.
SmithKline Beecham Biologicals SA (Belgium; unit of SmithKline Beecham plc; NYSE:SBH; U.K.)
Collaboration and license agreement on Aphton¿s Gonadimmune anti-gonado-tropin releasing hormone (anti-GnRH) synthetic peptide vaccines for diagnosis, treatment and prevention of GnRH-related cancers and other diseases
$15M (equity; % ND)
Companies will conduct clinical trials jointly; SmithKline will fund all costs of product develoment and approvals; SmithKline gets exclusive worldwide rights to Aphton¿s patents and technology; Aphton gets royalties but no upfront or milestone payments; SmithKline bought $5M in equity (0.24M shares at premium to market); Aphton has 2-year option to sell another $5M in equity to SmithKline; if option is exercised, SmithKline has 90 days to buy an additional $5M in equity (6/98)
Aradigm Corp.
Novo Nordisk A/S (NYSE:NVO; Denmark)
Agreement to jointly develop pulmonary delivery system for insulin (based on Aradigm¿s AERx system) and to evaluate its use in delivering other compounds for regulating blood glucose levels in diabetes
$50M (2.6% equity)
Novo Nordisk gets option to develop technology for delivery of compounds in 2 other therapeutic areas outside diabetes; Aradigm got $4M upfront in cash; Novo bought 0.3M newly issued shares for $5M (25% premium to market) and will buy another $5M in equity in future; Aradigm could get $36M in milestones; Novo will fund all development costs and both companies will fund final development of AERx diabetes system; Novo has exclusive worldwide marketing rights; Aradigm will initially manufacture products and gets a share of profits (6/98)
ArQule Inc.
The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ)
Collaboration; use of ArQule¿s Mapping Array program (small-molecule compound libraries) to discover lead compounds in various therapeutic areas
ND
4-year agreement; Johnson gets subscription to Mapping Array program for which it pays annual fees; ArQule will deliver 1.1M compounds over 4 years; Johnson gets non-exclusive license to ArQule¿s process of designing and manufacturing arrays; ArQule gets milestones and royalties (12/98)
Aviron
Becton Dickinson and Co. (NYSE: BDX)
Supply agreement; use of Becton Dickinson¿s AccuSpray non-invasive nasal spray delivery system for administration of Aviron¿s FluMist intranasal influenza vaccine
Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA)
Combinatorial chemistry agreement based on Axys¿ generic compound screening library (consists of multiple small-molecule synthetic organic compound libraries)
$20M
3-year agreement; Parke-Davis gets library plus enabling technologies and synthetic protocols for recreating the library and making others; Axys gets payments of $20; further details ND (6/98)
Axys Pharmaceuticals Inc.
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc SA; NYSE:RP; France)
Research collaboration on small molecule therapeutics that inhibit cathepsin S (cysteine protease associated with inflammation), initally for treating asthma
$80M
2-year collaboration, which Rhone-Poulenc can extend for additional 2 years; Rhone-Poulenc gets exclusive rights to products for treating respiratory diseases, atherosclerosis and rheumatoid arthritis; Axys gets $80M in research funds, license fees and milestones, as well as royalties (12/98)
Axys Pharmaceuticals Inc.
Roche Bioscience (division of Roche Holding Ltd.; Switzerland)
Functional genomics alliance; use of nematode Caenorhabditis elegans as animal model system to evaluate function of genes that may serve as drug targets for therapies for pain and other peripheral nervous system disorders
ND
Roche Bioscience will provide set of genes to which Axys will apply its functional genomics platform; Axys gets upfront fee and R&D funds; Roche Bioscience has option to license discovered targets for further development of diagnostic and antisense products; if it exercises option, Axys gets license fees, milestones and royalties; Axys retains rights to develop gene therapy and therapeutic protein products acting on targets; agreement for 15 months, but expandable to 24 months (6/98)
Axys Pharmaceuticals Inc.
Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE:AHP)
Pharmacogenomics agreement; clinical study of role played by polymorphism in cytochrome p450 3A4 gene in metabolism of 2 classes of marketed drugs
ND
Wyeth-Ayerst will conduct clinical study on Axys¿ gene variant; Axys will provide patient genotyping and intellectual property; further details ND (7/98)
Bio-Technology General Corp.
Swiss Serum and Vaccine Institute (Switzerland)
Development and licensing agreement on Bio-Technology General¿s 3rd generation recombinant hepatitis B virus vaccine (viral surface antigens S, pre-S1 and pre-S2 expressed in mammalian cells)
ND
Agreement covers scale-up and optimization of vaccine manufacturing process as well as clinical development, registration and marketing of product; companies will also develop combination vaccines; Swiss Serum will buy vaccine from Bio-Technology General and distribute in Western Europe, Latin America and other countries; BioTechnology General gets milestones and royalties (2/98)
BioChem Pharma Inc. (Canada)
SmithKline Biologicals SA (Belgium; unit of SmithKline Beecham plc; NYSE:SBH; U.K.)
Research collaboration on BioChem¿s influenza vaccine technologies, including cell-derived injectable and nasal delivery technologies (including Light-Biovector system licensed from Biovector Therapeutics SA)
ND
Initial period of joint development to be funded by both parties; companies will collaborate to market products in U.S.; SmithKline gets exclusive license elsewhere; SmithKline will manufacture for markets worldwide except Canada, where BioChem retains all exclusive rights; BioChem gets upfront and milestone payments (heads of agreement 6/98; finalized 12/98)
BioCryst Pharmaceuticals Inc.
The R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceuticals Inc. (both Johnson & Johnson companies; NYSE:JNJ)
Collaboration and license agreement on BioCryst¿s orally active influenza neuraminidase inhibitors for treating and preventing viral influenza
$55M (equity; % ND)
BioCryst gets $6M upfront and a $6M equity investment from Johnson & Johnson Development Corp. (J & J Development bought 0.92M newly issued shares at market for $6M total in 10/98); BioCryst also gets milestones and royalties; R.W. Johnson and Ortho get exclusive worldwide rights to products (9/98)
Bioject Medical Technologies Inc.
Merck & Co. Inc. (NYSE:MRK)
Use of Bioject¿s needlefree jet injection system to deliver selected Merck vaccines
ND
ND (7/98)
Caliper Technologies Corp.*
Hewlett-Packard Co. (NYSE:HWP)
Agreement to jointly develop 1st-generation lab-on-a-chip technology (uses liquid integrated circuitry to create chemical processing systems on a microchip)
$100M
Companies together will invest $20M over next year to develop miniaturized instruments and then $80M over following 4 years to further develop and commercialize technology; Hewlett-Packard will develop instrumentation; Caliper will design, develop and manufacture chip (5/98)
Cambridge NeuroScience Inc.
Bayer Corp. (unit of Bayer AG; Germany)
Research collaboration on Cambridge Neuro¿s recombinant glial growth factor 2 (stimulates re-myelination of nerve cells) for treating neurodegenerative diseases, including multiple sclerosis
$26M
Bayer responsible for all development costs, including reimbursement of Cambridge Neuro¿s research costs; Bayer gets exclusive worldwide manufacturing and marketing rights; Cambridge Neuro gets $26M in cash and milestones, as well as royalties; companies have already worked together (for 1 year) to develop manufacturing process for product (12/98)
Cantab Pharmaceuticals plc (U.K.)
Kaketsuken (Japan)
Research and option agreement to develop Cantab¿s DISC VSV virus (genetically disabled live Varicella zoster virus) as prophylactic vaccine for chickenpox and shingles
ND
Kaketsuken will fund research at Cantab for 2 years in return for option to license all product rights for Japan and certain other Asian territories; once research phase completed, parties will form development and marketing agreement, under which Cantab will get license and milestone fees and royalties, and retain marketing and sublicensing rights for rest of world (1/98)
Cell Genesys Inc.
Japan Tobacco Inc. (Japan)
Collaboration on selected products from Cell Genesys¿ GVAX cancer vaccine program (gene therapy, both autologous and allogeneic approaches to treating tumor cells ex vivo with granulocyte macrophage-colony stimulating factor to stimulate immune response; currently in Phase I/II trials for prostate cancer, lung cancer and melanoma); collaboration¿s initial focus on 2 targets (prostate cancer and an unidentified target)
$152.7M
Companies will share equally both product development costs and profits; Cell Genesys gets marketing rights in North America; Japan Tobacco gets rights in Japan, Taiwan and Korea; companies will share equally Europe and rest of world; Cell Genesys gets $12.7M on signing, $2.5M at 1-year anniversary, $27.5M in R&D funds over 1st 3 years and $80M in milestones through regulatory approvals of 2 products; Cell Genesys also gets $30M loan to cover its costs for Phase III trials; companies will also support ongoing clinical trial in Japan of GVAX for kidney cancer; if parties agree to proceed with development of this product, Cell Genesys gets reimbursed for R & D plus other non-specified payments; of $152.7M total funds, Cell Genesys gets $45M during 1st 2 years (12/98)
Cellegy Pharmaceuticals Inc.
3M Drug Delivery Systems
Research agreement to evaluate combining Cellegy¿s Celledirm inflammatory response modulator technology with 3M¿s Latitude transdermal drug delivery system
ND
ND (6/98)
Cellomics Inc.*
Merck & Co. Inc. (NYSE:MRK)
Agreement to develop cell-based high-content screening platform (uses fluorescence-based assays)
ND
ND (6/98)
Cellomics Inc.*
Warner-Lambert Co. (NYSE:WLA)
Agreement to develop fluorescence-based cytotoxicity assays
ND
ND (8/98)
Cerebrus Holdings plc (U.K.)
Eli Lilly and Co. (NYSE:LLY)
Joint development of Lilly¿s drug CEB-1555 (selective 5HT1A receptor agonist) for treating delayed and anticipatory emesis associated with cancer chemotherapy
ND
Cerebrus licensed the compound and will conduct clinical trials through Phase II; Lilly then has option of completing clinical development alone or in collaboration with Cerebrus; if it doesn¿t exercise option, Cerebrus can develop with or without new partner (9/98)
ChemTrak Inc. (OTC Bulletin Board:CMTR)
Pfizer Inc. (NYSE:PFE)
Contract research; ChemTrak will develop disposable, quantitative finger-stick whole blood test for one of Pfizer¿s drugs in development
$2.4M
Pfizer will pay $0.4M quarterly over next 18 months for test development; ChemTrak will be exclusive manufacturer of test (which uses its AccuMeter technology) (6/98)
Chiron Corp.
Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)
Strategic collaboration to identify small-molecule inhibitors of hepatitis C virus (HCV)
ND
Chiron gets upfront payment; companies will contribute equal resources and funding for all phases of product development; companies will share worldwide marketing rights; Chiron will provide its scientific expertise on HCV and non-exclusive rights to all HCV targets covered by its patents and patent applications (2/98)
Chiroscience Group plc (U.K.)
Bristol-Myers Squibb Co. (NYSE:BMY)
Research and licensing agreements on use of matrix metalloproteinase (MMP) inhibitors for treating cancer; includes Chiroscience¿s 2nd-generation oral compounds D2163 (currently in U.K. Phase I trials) and D1927; also covers discovery of new MMP inhibitors via Chiroscience¿s gene expression technology
ND
3-year agreement; Bristol-Myers gets worldwide license on D2163 and D1927; Chiroscience gets access fees, research funds, milestone payments and royalties; Bristol-Myers gets all rights to new and jointly selected MMP inhibitors that are developed for oncology; Chiroscience retains rights in all other therapeutic areas (2/98)
Chiroscience Group plc (U.K.)
Penwest Pharmaceuticals Co. (NASDAQ:PPCO)
Collaboration to develop controlled-release oral formulations of drug isomers
ND
3-year agreement; both companies will fund R&D and will share profits equally; Chiroscience will perform chemical, preclinical and clinical development; Penwest will perform pharmacokinetic analysis and product formulation (12/98)
Chrysalis BioTechnology Inc.*
OrthoLogic Corp. (NASDAQ:OLGC)
Option on license for Chrysalis¿ synthetic 23-amino-acid-peptide chrysalin for orthopedic applications, initially for healing of fractures
$0.8M (equity; % ND)
OrthoLogic acquired minority equity stake in Chrysalis for $0.75M; OrthoLogic has 9-month option on worldwide exclusive license to orthopedic applications of chrysalin; Ortho-Logic can continue and expand option contingent on preclinical results; OrthoLogic will fund R&D, milestones and clinical trials (1/98)
Chrysalis International Corp. and its wholly owned subsidiary Chrysalis DNX Transgenic Sciences
Pfizer Inc. (NYSE:PFE)
Genomics-based transgenic research contract and collaboration to identify and validate new therapeutic targets for 2 major disease categories via Chrysalis¿ transgenic mouse and rat lines
ND
Chrysalis will use its high capacity transgenic animal capabilities to identify and validate new therapeutic targets from genetic data generated by Pfizer¿s genomics initiative; Pfizer will fund research for 2 years (1/98)
Cima Labs Inc.
Organon (unit of Akzo Nobel NV; the Netherlands)
Development and license option agreement; development of OraSolv fast-dissolve formulation of one of Organon¿s prescription drugs
ND
Cima will develop product in exchange for option and development fees; Organon gets license option (12/98)
Cistron Biotechnology Inc. (OTC Bulletin Board:CIST)
Pasteur Merieux Connaught (unit of Rhone-Poulenc Group; NYSE:RP; France)
Collaboration and option agreement on use of Cistron¿s interleukin-1 beta as adjuvant for therapeutic and preventative vaccines
$32.9M (equity; % ND)
Pasteur Merieux has 3-year option to acquire exclusive license to technology; Pasteur Merieux will pay $0.9M over 3 years to fund R&D; if it exercises option, Cistron gets $31M in milestones, plus royalties; Pasteur Merieux also paid $1M total for 1.33M shares Cistron common stock and 3-year warrant to buy 0.67M shares at $0.25 per share (letter of intent 7/98; finalized 10/98)
Compugen Ltd.* (Israel)
Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA)
Bioinformatics collaboration; use of Compugen¿s LEAD bioinformatics technology to identify drug targets based on analysis of expressed sequence tags and genomic databases
ND
3-year agreement; details ND (11/98)
Connetics Corp.
Suntory Pharmaceuticals (division of Suntory Ltd.; Japan)
Development, supply and commercialization agreement on ConXn (recombinant human relaxin-H2) for treating scleroderma
$14M
Suntory will pay $1.6M license fee and $12.4M in development milestones (including in U.S.); Suntory responsible for all development and commercialization expenses in Japan; Connetics gets royalties; Suntory will buy ConXn materials from Connetics; Connetics retains rights to all other indications in Japan and all ex-Japan rights on product (4/98)
Cortech Inc. (OTC Bulletin Board: CRTQ)
United Therapeutics Corp.*
Product development and license agreement on Cortech¿s elastase inhibitor CE-1037 for treating emphysema and other diseases
ND
Cortech gets upfront license fee of $0.25M; United Therapeutics will fund all future product development; Cortech gets milestones and royalties (11/98)
CuraGen Corp.
Glaxo Wellcome plc (NYSE:GLX; U.K.)
Pharmacogenomics-based collaboration; use of CuraGen¿s GeneCalling and SeqCalling technologies to evaluate activity of undisclosed Glaxo drug candidates in preclinical studies in animals to guide selection of drug candidates for human trials (gene expression profiling)
$48M
5-year collaboration; CuraGen gets $2.75M annually plus milestones and royalties; CuraGen will evaluate various compounds across Glaxo¿s therapeutics areas and identify gene responses associated with toxicity and efficacy (11/98)
Cytel Corp.
Japan Tobacco Inc. and Marukin Shoyu Co. Ltd. (both Japan)
Technology agreements on 2 enzymes for use in Cytel¿s carbohydrate synthesis technology
ND
Cytel gets exclusive rights to enzymes; Japan Tobacco will supply technology for making particular bacterial enzyme; Cytel has 3-year option to evaluate and take out exclusive worldwide license; Japan Tobacco retains right to use enzyme for its own purposes; Cytel also gets exclusive worldwide rights to Marukin¿s enzyme and will pay Marukin fees and royalties (10/98)
Cytoclonal Pharmaceutics Inc.
Bristol-Myers Squibb Co. (NYSE:BMY)
License and research agreement; use of microbial fermentation to produce paclitaxel and/or other taxanes; also, use of specific genes to enhance production
$50M
Cytoclonal could get $50M in research and support fees and milestones, as well as royalties (6/98)
CytoMed Inc.*
UCB Pharma (division of UCB Group; Belgium)
Research collaboration on therapeutics for major inflammatory diseases (via small molecules that modulate specific anti-inflammatory activities)
ND
UCB will fund joint research program; further details ND (3/98)
deCode Genetics Inc.* (Iceland)
F. Hoffmann-La Roche Ltd. (Switzerland)
Collaboration to discover disease genes for use in therapeutics and diagnostics; use of Icelandic population database to discover genes that predispose people to developing 12 common diseases (4 cardiovascular; 4 psychiatric/neurologic; 4 metabolic); collaboration also includes pharmacogenomics component
$200M (equity; % ND)
5-year collaboration; deCode gets up to $200M (including equity investment, research funds and milestone payments); Roche gets rights to develop small-molecule drugs and drugs based on gene products, as well as diagnostics; deCode retains rights to gene and antisense therapies (2/98)
Dendreon Corp.*
Kirin Brewery Co. Ltd. (Japan)
Collaboration; development of therapeutics based on Dendreon¿s dendritic cell technology; also, research agreement to jointly develop dendritic cells as products per se
ND (includes equity)
Kirin gets exclusive marketing rights in Japan and other Asian and Oceanic countries; companies will co-commercialize some products in Europe; Kirin made equity investment in Dendreon and will buy more equity in Dendreon¿s IPO; Kirin has option to license dendritic cell products; Dendreon gets signing fee, milestones and royalties; Dendreon gets option for exclusive license to products developed by Kirin based on technology, which it would market in North America (12/98)
DepoMed Inc.
The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE: JNJ)
Research collaboration on use of DepoMed¿s Gastric Retention System (orally administered controlled release system) with a Johnson & Johnson drug
ND
ND (3/98)
Desmos Inc.*
Guidant Corp. (NYSE:GDT)
Collaboration to test feasibility of improving stent biocompatibility by coating them with Desmos¿ bioenhancing materials
ND
Guidant will provide financial support; further details ND (7/98)
Diatide Inc.
Merck & Co. Inc. (NYSE:MRK)
License agreement on Merck¿s technology (not described) for use in Diatide¿s pulmonary imaging product P748 (currently in Phase II trials for imaging pulmonary embolisms)
ND
Diatide gets non-exclusive license to develop, manufacture and market products covered by Merck¿s patent (12/98)
Dura Pharmaceuticals Inc.
Eli Lilly and Co. (NYSE:LLY)
Collaboration; use of Dura¿s Spiros pulmonary drug delivery technology for insulin products (powder for inhalation)
ND
Dura gets upfront payment, research funds and milestones; Dura also gets manufacturing fees and royalties; Lilly gets worldwide marketing rights (9/98)
Elan Corp. plc (Ireland)
Medi-Ject Corp. (NASDAQ:MEDJ)
License agreement on Elan¿s injectable drug delivery technology
ND
Medi-Ject gets exclusive license; separately, Elan invested $1M in Medi-Ject in exchange for preferred stock and warrants (11/98)
Elan Pharmaceutical Technologies (division of Elan Corp. plc; Ireland)
Novartis Pharmaceuticals Corp. (unit of Novartis AG; Switzerland)
Development and licensing agreement on use of Elan¿s extended-release drug delivery technology with a Novartis prescription drug (not disclosed)
$18M
Elan will reformulate Novartis¿ drug and test its pharmacokinetics in human trials; Novartis will conduct all other clinical trials and product registrations; Elan gets development and licensing fees of $18M total, as well as royalties; Elan will manufacture product for Novartis and gets manufacturing fees (1/98)
Elan Pharmaceutical Technologies (division of Elan Corp. plc; Ireland)
Solvay Pharmaceuticals Inc. (member of The Solvay Group; Belgium)
Agreement on use of Elan¿s extended-release drug delivery technology with Solvay¿s prescription drug Luvox (fluvoxamine; a selective serotonin re-uptake inhibitor for treating obsessive compulsive disorder and depression)
ND
Elan will develop new dosage formulation of Luvox; Solvay will conduct all clinical trials and product registrations; Elan gets development and licensing fees as well as milestones; Elan will manufacture new formulation and gets manufacturing fees; Elan also gets royalties (2/98)
Endocyte Inc.*
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc SA; NYSE:RP; France)
Research collaboration; use of Endocyte¿s vitamin-based vector technology for systemic delivery of gene therapies for cancer; initially focus on use of folate (folic acid) receptors
$40M
Rhone-Poulenc Rorer gets exclusive license for use of folate receptors for delivery of oncology gene therapies; it has 2-year option to expand scope of license to include other vitamin-receptor patents; Endocyte gets $40M in license fees, R&D funding and milestones (12/98)
EnzyMed Inc.*
Merck & Co. Inc. (NYSE:MRK)
Research collaboration; use of EnzyMed¿s combinatorial biocatalysis technology to optimize certain of Merck¿s compounds
ND
EnzyMed gets upfront fee, milestones and royalties; details ND (12/98)
Epix Medical Inc.
Mallinckrodt Inc. (NYSE:MKG) and General Electric Medical Systems (NYSE:GE)
Collaboration to improve and expand capabilities of magnetic resonance imaging for diagnosing coronary artery disease and peripheral vascular disease
ND
Companies will develop hardware and software to be used with Epix¿s MS-325 injectable contrast agent; financial details ND (1/98)
Epix Medical Inc. and Mallinckrodt Inc. (NYSE:MKG)
Pfizer Inc. (NYSE:PFE)
Collaboration on use of AngioMark enhanced magnetic resonance imaging in diagnosis and monitoring of female sexual arousal dysfunction
ND
ND (9/98)
Ergo Science Corp.
The R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical Inc. (units of Johnson & Johnson; NYSE: JNJ)
Collaboration to develop Ergoset (bromocriptine mesylate, dopamine agonist) and other products as treatments for Type II diabetes and obesity (NDA accepted for filing 10/97)
$40M (equity; % ND)
Ergo gets $10M license fee plus $10M equity investment; Ergo also gets $20M on FDA approval of Ergoset for Type II diabetes; companies will share equally costs of developing and commercializing Ergoset and other products; they will also share profits equally; Ergo gets royalties on sales outside U.S.; Ergo gets additional milestones for other products; agreement subject to antitrust considerations (2/98)
Gene Logic Inc.
NV Organon (unit of Akzo Nobel; the Netherlands)
Gene expression database alliance; use of Gene Logic¿s Normal database (reference set of quantitative gene expression profiles in mouse, rat and human tissues) and its bioinformatics system for analysis and integration of gene expression data
ND
3-year agreement; Organon gets non-exclusive access to database and bioinformatics system for use in its internal drug discovery program; Gene Logic will also construct gene expression database exclusively for Organon; Organon responsible for worldwide development and commercialization of therapeutics; Gene Logic retains rights to diagnostics and certain therapeutics; Gene Logic gets research funds, license fees, milestones and royalties (1/98)
Gene Logic Inc.
SmithKline Beecham plc (NYSE:SBH; U.K.)
Bioinformatics collaboration; licensing of Gene Logic¿s Object Protocol Model (OPM)-based bioinformatics system to develop series of customized databases for integrating public and proprietary genomic and biological data sources into Smith-Kline¿s data mining process
ND
SmithKline licensed OPM system and software tools; Gene Logic retains right to license software and products developed under collaboration to 3rd parties; Gene Logic gets licensing fees and funding; financial terms ND (5/98)
Gene Logic Inc.
Wyeth-Ayerst Laboratories (division of American Home Products Corp.; NYSE:AHP)
Pharmacogenomics alliance; use of Gene Logic¿s gene expression technology to develop database of gene expression profiles to predict preclinical toxicity of Wyeth-Ayerst compounds
ND
During 1st year of agreement, companies will share costs of selecting compounds and tissue samples to be analyzed;Wyeth-Ayerst also gets access to flow-through chip technology; Gene Logic may non-exclusively license products developed to 3rd parties (6/98)
Genentech Inc.
Dako A/S (Denmark)
Agreement to develop in vitro diagnostic kit for screening breast cancer patients for overexpression of HER2 (growth factor receptor) and to identify their potential eligibility to be treated with Herceptin (humanized anti-HER2 monoclonal antibody; FDA-approved)
ND
Dako gets license to develop immuonhistochemical diagnostic kit; Genentech gets royalties; further details ND (3/98)
Genentech Inc.
Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)
Development and licensing agreement on Genentech¿s thrombopoietin (TPO) for treating thrombocytopenia in cancer patients receiving chemotherapy and in stem cell transplants (currently in Phase II trials)
$35M
Pharmacia & Upjohn gets exclusive worldwide rights to TPO; companies will jointly develop product; Genentech will manufacture product for development work and commercialization; Pharmacia & Upjohn will fund future development costs and pay $35M in license fees through 2000 (including initial $12M fee); if product approved for marketing, Genentech gets final transfer payment and royalties; Genentech will conduct clinical trials in myeloablative therapy; Pharmacia & Upjohn will conduct clinical trials for all other indications (1/98)
Genetronics Biomedical Ltd.
Ethicon Inc. (unit of Johnson & Johnson; NYSE:JNJ)
Licensing and supply agreement on Genetronics¿ electroporation for delivery of chemotherapeutic drugs to solid tumors
$21M (equity; % ND)
Johnson & Johnson Development Corp. will buy $6M in stock at market price; Genetronics gets $15M upfront license fee, milestones and percent of net sales; Ethicon gets worldwide exclusive rights to technology; Ethicon will help develop and test system in clinic; Ethicon will conduct regulatory activities worldwide except in Canada, where Genetronics retains rights (10/98)
Genome Pharmaceuticals Corp. AG* (Germany)
Byk Gulden (subsidiary of Altana AG; Germany)
Research collaboration; use of Genome Pharmaceuticals¿ functional genomics technology to discover genomic targets for controlling infections caused by Helicobacter pylori and Chlamydia pneumoniae
$30M
5-year collaboration; Byk Gulden will fund 3 specific research projects; Genome Pharmaceuticals gets upfront payment and milestones for all targets accepted by Byk Gulden; it also gets success fees on commercialization; Genome Pharmaceuticals can use targets not accepted by Byk Gulden as basis for other partnerships (12/98)
Genome Therapeutics Corp.
Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)
License agreement on Genome Therapeutics¿ microbial sequence database PathoGenome
ND
Hoechst Marion gets exclusive access to database; Genome Therapeutics gets annual subscription fees and royalties on any small molecule products; Genome Therapeutics retains certain rights for use of genes or gene products (10/98)
Genomica Corp.*
Glaxo Wellcome plc (NYSE:GLX; U.K.)
License agreement; use of Genomica¿s bioinformatics gene discovery software system for gene discovery and functional analysis
ND
ND (7/98)
Genset SA (France)
Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)
Pharmacogenomics collaboration; use of Genset¿s high resolution bi-allelic marker map to identify genetic markers in patients involved in clinical study of a Pharmacia & Upjohn drug (i.e., responders and nonresponders)
ND
2-year agreement; Genset gets research fees, milestones and royalties; it also gets royalties on 2nd-generation compounds based on genes identified; financial terms ND (10/98)
Genset SA (France)
Wyeth-Lederle Vaccines (unit of American Home Products Corp.; NYSE:AHP)
License agreement; use of Genset¿s genomic data on Chlamydia pneumoniae and C. trachomatis for vaccines
$15M
Wyeth-Lederle gets exclusive worldwide rights to patent applications covering entire L2 genomic sequences of both organisms for use in vaccines; Genset gets $15M initial license fee and milestones, as well as royalties; Genset retained rights for diagnostic, small molecule, therapeutic protein, gene therapy and cell therapy applications of genomic data (8/98)
Gensia Sicor Inc.
Asta Medica AG (Germany)
Joint development of depot formulations of undisclosed peptides as cancer therapies (long-acting drug delivery)
ND
Companies will co-promote product in North America; further details ND (5/98)
GenVec Inc.*
Asahi Chemical Industry Co. Ltd. (Japan)
Licensing agreement on all gene therapy applications of tumor necrosis factor alpha gene (to be developed for use in combination with radiation therapy)
ND
GenVec licensed U.S. rights to gene; further details ND (4/98)
GenVec Inc.*
Fuso Pharmaceutical Industries Ltd. (Japan)
Collaboration to develop gene therapies for cancer
ND (includes equity)
GenVec gets R&D funding for 5 years as well as milestones; Fuso bought undisclosed equity stake in GenVec on signing; Fuso gets rights in Japan with option for Korea and Taiwan; GenVec gets royalties; GenVec retains right to develop and commercialize products in rest of world (4/98)
GenVec Inc.*
Varian Biosynergy (subsidiary of Varian Associates Inc.)
Joint development of cancer therapies by combining targeted radiation therapy with GenVec¿s gene therapy (in vivo production of therapeutic products by gene transfer following exposure to radiation)
ND
Companies will collaborate in both preclinical and clinical development; Varian will develop equipment and software for delivery of targeted radiation therapy; companies each retain rights to their respective products and technologies (4/98)
Genzyme Molecular Oncology
Bayer Corp. (unit of Bayer AG; Germany)
Genomics collaboration; use of Genzyme Molecular¿s SAGE technology (serial analysis of gene expression) to identify genes for development of future drug candidates
ND
Service agreement; Genzyme Molecular will provide gene expression analysis for Bayer¿s drug candidates (8/98)
Genzyme Molecular Oncology
Merck & Co. Inc. (NYSE:MRK)
License agreement on Genzyme Molecular¿s methods for screening small-molecule compounds that inhibit binding of cancer-related protein MDM2 to the p53 protein (binding prevents p53 from activating genes that control cell division)
$8M
Merck gets non-exclusive rights to cancer assay methods; Genzyme Molecular gets upfront payment and $8M in milestones as well as royalties on sales of any therapeutic products (2/98)
Genzyme Molecular Oncology
Schering-Plough Corp. (NYSE:SGP)
Research and option agreement; use of Genzyme Molecular¿s lipid gene delivery systems with several of Schering-Plough¿s genes, including p53 tumor suppressor gene, to develop gene therapy products
$80M
Schering-Plough has option to exclusively license Genzyme Molecular¿s gene delivery systems for use with 6 of its genes; if it exercises option, Genzyme Molecular gets license fees, research funding, and milestones totaling $80M; Genzyme Molecular gets $7M over next year for research on p53 gene therapy product (1st of 6 genes); Genzyme Molecular also gets royalties on sales (1/98)
Genzyme Molecular Oncology
Schering-Plough Corp. (NYSE:SGP)
License agreement on Genzyme Molecular¿s p53 gene therapy rights
$40M
This is separate agreement from 1/98 research alliance; Genzyme Molecular gets $5M upfront fee and $35M in patent, development and sales milestones, as well as royalties; Schering-Plough gets worldwide license on use of p53 gene in gene therapy products; Genzyme Molecular retains rights in areas outside gene therapy (diagnostics, therapeutics) (10/98)
Hyseq Inc.
Kirin Brewery Co. Ltd. (Japan)
Gene discovery collaboration; use of Hyseq¿s gene discovery platform to target genes involved in cell growth regulation from specific cell lines of Kirin¿s
$3M
Companies will co-develop and co-market products; Hyseq gets $3M for 1st phase of collaboration; Hyseq retains rights to 100% of North American profits and will pay milestones and royalties to Kirin; Kirin has rights in Asia and Oceania; companies will share profits equally from sales in Europe and rest of world; 2-year alliance (10/98)
Icos Corp.
Eli Lilly and Co. (NYSE:LLY)
Formation of joint venture to develop and market phosphodiesterase type 5 (PDE5) inhibitors as oral therapeutics for male and female sexual dysfunction (IC 351 currently in Phase II trials for male erectile dysfunction)
$75M
Lilly will fund 50/50 joint venture for 1st 3 years, after which companies will contribute equally; Icos will contribute intellectual property and research platform associated with IC 351; Icos gets $75M in upfront payment and milestones; joint venture will market products in North America and Europe; Lilly will market elsewhere and pay royalties to Icos (10/98)
Igen International Inc.
Bristol-Myers Squibb Co. (NYSE:BMY)
Rights to Igen¿s Origen high-throughput drug discovery system (based on electrochemiluminescence)
ND
Bristol-Myers will purchase Origen system and get a pre-launch production model; further details ND (10/98)
Igen International Inc.
Medinnova SF (Norway)
License agreement; use of Medinnova¿s cardiac marker (N-terminal pro-atrial naturietic peptide) for detecting and monitoring cardiac-related diseases
ND
Igen acquired exclusive worldwide rights to marker, which it will use in an Origen-based test (7/98)
Igen International Inc.
Schering-Plough Corp. (NYSE:SGP)
Rights to Igen¿s Origen high-throughput drug discovery system (based on electrochemiluminescence)
ND
Schering-Plough will purchase Origen system and get a prelaunch production model; further details ND (11/98)
Ilex Oncology Inc.
Symphar SA (Switzerland)
Joint development agreement on Symphar¿s orally active, apoptosis-inducing compound SR-45023A (bisphosphonate ester derivative that stimulates nuclear receptor FXR) for treating cancer
ND
Ilex will conduct all clinical development; Ilex can negotiate for all future rights to SR-45023A; further details ND (9/98)
ImClone Systems Inc.
Merck KgaA (Germany)
Collaboration on ImClone¿s chimeric monoclonal antibody C225 (inhibits epidermal growth factor receptor) for treating various solid tumors (about to enter Phase III trials)
$90M (equity; no greater than 19.9%)
This is 2nd collaboration between companies; Merck gets exclusive rights to drug outside North America, except in Japan, where partners will co-develop; ImClone retains rights in North America; ImClone gets $30M in upfront fees and early cash-based milestones, $30M in late-stage, equity-based milestones (but not more than 19.9% total equity stake) and $30M in credit line to build commercial manufacturing facility; Merck will fund clinical development outside North America; ImClone will develop product exclusively in North America; ImClone gets royalties on Merck¿s sales (12/98)
ImmuLogic Pharmaceutical Corp.
Heska Corp. (NASDAQ:HSKA)
License agreement; use of ImmuLogic¿s recombinant allergen technology for diagnosis, immunotherapy and gene therapy applications in humans and companion animals
ND
Heska gets exclusive worldwide license to technology (except in Japan, where rights are non-exclusive); ImmuLogic gets license fees, milestones and royalties (6/98)
ImmuLogic Pharmaceutical Corp.
Sankyo Co. Ltd. (Japan)
License agreement on certain of ImmuLogic¿s patents for recombinant proteins and peptides; for use in treating allergy to Japanese cedar pollen
ND
ImmuLogic gets license fee, milestones and royalties; further details ND (5/98)
The Immune Response Corp.
Schering-Plough Corp. (NYSE:SGP)
Research collaboration and option agreement to combine Immune Response¿s GeneDrug gene delivery technology with Schering¿s interferon (IFN) alfa-2b gene (among others) as gene therapy products for treating hepatitis B and C virus infection
$80M
In preclinical stage of agreement (1 year), Immune Response gets $5M in initial fees, reimbursement and milestones related to delivery of IFN alfa-2b gene; if Schering exercises option to use delivery system for additional genes, it will pay $75M in licensing fees and milestones; Immune Response also gets royalties (7/98)
Immunex Corp.
SmithKline Beecham plc (NYSE:SBH; U.K.)
License agreement; use of Immunex¿s granulocytecolony stimulating factor receptor in SmithKline¿s R&D program (to screen and develop small-molecule compounds)
ND
SmithKline gets non-exclusive license to protein; Immunex gets upfront fee, milestones and royalties (8/98)
Immunomedics Inc.
Beckman Coulter Inc. (NYSE:BEC)
Formation of new company, IBC Pharmaceuticals, to develop cancer drugs via affinity-enhancement technology (use of bi-specific humanized monoclonal antibodies to deliver therapeutic radionuclides to cancer cells)
ND
Beckman Coulter will provide its affinity enhancement technology to new company and will join with Immunomedics to raise private capital to fund the venture; both ¿parent¿ companies will share patents and technologies; IBC Pharmaceuticals will develop affinity-enhancement technology (letter of intent 4/98; finalized 6/98)
Immusol Inc.*
Pfizer Inc. (NYSE:PFE)
Genomic-based research collaboration to validate therapeutic targets in Pfizer¿s pipeline via Immusol¿s hairpin ribozyme technology and in vivo assay model to determine gene function in human cell lines
ND
Immusol will design specific ribozymes for each candidate gene target sequence of Pfizer¿s; further details ND (3/98)
Incyte Pharmaceuticals Inc.
Bayer Corp. (unit of Bayer AG; Germany)
Genomic database agreement for access to Incyte¿s LifeTools bioinformatics software and LifeSeq PD (annotated version of public cDNA database)
ND
Bayer¿s global pharmaceutical division will use software for data management and to support research; Incyte will provide consultation services; Incyte gets subscription fees; further details ND (4/98)
Incyte Pharmaceuticals Inc.
Monsanto Co. (NYSE:MTC)
Large-scale, genome-wide application of Incyte¿s gene expression microarray technology for functional genomics applications in plant, animal and human genomes
ND
3-year agreement (this is 2nd agreement between companies); Monsanto gets access to up to 50,000 DNA microarrays for use across its life sciences programs; Incyte will provide data from custom and prefabricated DNA microarrays, software to manage and analyze data, and consulting services; other terms ND (5/98)
Incyte Pharmaceuticals Inc.
Schering-Plough Corp. (NYSE:SGP)
Broad genomic data collaboration; use of Incyte¿s microarray technology and databases (including LifeSeq and LifeSeq FL) in Schering-Plough¿s research programs
ND
Schering-Plough gets access to data from Incyte¿s custom and prefabricated DNA microarrays; Incyte gets technology access and per-array fees; multiyear collaboration; financial terms ND (10/98)
Inhale Therapeutic Systems
Eli Lilly and Co. (NYSE:LLY)
Collaboration on use of Inhale¿s deep-lung delivery system for macromolecules to formulate an unspecified protein drug for Lilly
$20M
Inhale gets $20M in R&D funds and milestones; Lilly gets worldwide rights to formulated drug; Inhale gets royalties; Inhale will manufacture packaged powders for and supply inhalation devices to Lilly; Lilly responsible for clinical trials, product registration and marketing (1/98)
Inspire Pharmaceuticals Inc.*
Kissei Pharmaceutical Co. Ltd. (Japan)
Strategic collaboration; development of Inspire¿s inhaled respiratory therapeutic INS 365 (activates P2Y2 receptor to stimulate mucociliary clearance) for treating chronic obstructive pulmonary diseases
$17.5M (equity; % ND)
Inspire gets $17.5M in upfront fee, equity investment and milestones; Inspire also gets R&D funds and royalties; Kissei gets exclusive rights in Japan plus access to 2nd-generation analogues of INS 365 for respiratory uses (9/98)
Integra LifeSciences Corp.
Johnson & Johnson Professional Inc. (subsidiary of Johnson & Johnson; NYSE:JNJ)
Strategic alliance on an absorbable, collagen-based implant (combined with an RGD peptide) for repairing and regenerating articular cartilage
$12M
Integra gets $12M in milestones; Johnson & Johnson will fund all development costs beyond pre-clinical stage; Integra will manufacture product; Johnson & Johnson will develop arthroscopic instrumentation to be used in surgeries; Johnson & Johnson gets worldwide marketing rights (2/98)
Intercardia Inc.
Opocrin SpA (Italy)
License agreement; use of Opocrin¿s OP2000 (oligosaccharide derived from heparin) for treating inflammatory bowel disease
$1M
Intercardia gets exclusive worldwide license except in Japan and South Korea; Intercardia will conduct clinical trials; Opocrin gets $1M in license fee as well as milestones (letter of intent 3/98; final agreement 7/98)
IntraBiotics Inc.*
Biosearch Italia SpA (Italy)
Licensing and supply agreement for Ramoplanin (antibacterial agent for treating multi-drug-resistant bacteria, especially Staphylococcus aureus and Enterococcus faecalis)
ND
IntraBiotics will conduct U.S. Phase II clinical trials; IntraBiotics gets commercialization rights in U.S. and Canada; Biosearch gets licensing fee, milestones, royalties and bulk supply payments; Biosearch will manufacture drug substance; IntraBiotics will formulate and package it (5/98)
Irori Inc.*
Bristol-Myers Squibb Co. (NYSE:BMY)
Combinatorial chemistry collaboration; development of ultra-high throughput combinatorial chemistry system using Irori¿s Nano-Reactor technology (miniaturized micro-reactors for screening very large numbers of single compounds)
$14.5M (equity; % ND)
Companies will co-develop the NanoReactor in this 2-year collaboration; Bristol-Myers will buy $4.5M equity stake in Irori and pay milestones and licensing fees of $10M; additional details ND (6/98)
Irori Inc.*
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc Group; NYSE:RP; France)
Combinatorial chemistry collaboration; development of ultra-high throughput combinatorial chemistry system using Irori¿s Nano-Reactor technology (miniaturized micro-reactors for screening very large numbers of single compounds)
$10.5M (equity; % ND)
2-year collaboration; Irori gets $0.8M on signing; Rhone-Poulenc will buy $4.5M in Irori equity and will pay licensing fee and milestones; Rhone-Poulenc has option to buy an additional NanoReactor system (6/98)
Isis Pharmaceuticals Inc.
Merck & Co. Inc. (NYSE:MRK)
Research collaboration on small-molecule drugs for treating hepatitis C virus (HCV) infection
$50M
3-year collaboration; companies will jointly design and synthesize small-molecule compounds, which Merck will screen in its enzymatic assays for HCV replication inhibitors; Isis gets annual research funding, one-time technology access fee, milestones and royalties; Merck has commercial rights; Isis retains right to use technology developed in collaboration in its antisense program (6/98)
Isis Pharmaceuticals Inc.
Zeneca Pharmaceuticals (unit of Zeneca Group plc; NYSE:ZEN; U.K.)
Research collaboration on antisense-based drugs for treating cancer; initial focus on 2 unidentified molecular targets
$40M
3-year collaboration; Isis will create product candidates; companies will jointly screen these for undisclosed targets; Zeneca responsible for product development; Isis gets $40M, composed of technology access fee, annual research funds and milestones, as well as royalties; Zeneca gets exclusive worldwide rights to drugs; collaboration is extendable into additional targets in cancer and other therapeutic areas (12/98)
Kosan Biosciences Inc.*
The R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical Inc. (both Johnson & Johnson companies; NYSE:JNJ)
Research and license agreement; use of Kosan's combinatorial biosynthesis technology to make macrolide antibiotics (generates analogues of bioactive natural products via genetically engineered biosynthetic pathways)
ND
Kosan gets upfront payment, multiyear research funding, milestones and royalties; Johnson & Johnson companies get worldwide rights to antibacterial products; Research Institute responsible for product development; Ortho will market in U.S.; other Johnson & Johnson companies will market elsewhere (10/98)
DuPont will subscribe to Lexicon's OmniBank database and also gets non-exclusive license to Lexicon's positive-negative selection and isogenic DNA patent portfolio; Lexicon gets license to DuPont's Cre-lox technology and certain sub-licensing rights; Lexicon gets exclusive rights to use Cre-lox to practice gene trapping in mouse embryonic cells; companies will pay each other royalties (8/98)
Ligand Pharmaceuticals Inc.
SmithKline Beecham plc (NYSE:SBH; U.K.)
Collaboration on smallmolecule drugs that modulate signaling pathway controlled by leptin; use of Ligand's STATS technology (signal transduction and activator of transcription) to develop oral drugs for treating or preventing obesity
$9M (equity; % ND)
SmithKline will buy 0.27M shares Ligand common stock for $5M ($18.22/share, premium to market) and will also pay $1M for a 5-year warrant to buy 0.15M shares at $20/each; SmithKline will buy more stock on achievement of one specific milestone and will pay cash for subsequent milestones; SmithKline gets exclusive worldwide rights to products; Ligand gets royalties; subject to antitrust considerations (3/98)
LJL BioSystems Inc.
SmithKline Beecham plc (NYSE:SBH; U.K.)
Advanced technology access program for LJL's high-throughput screening systems, especially FLARe platform (fluorescence-based assays)
ND
SmithKline gets early access to LJL's advanced technologies (9/98)
MacroChem Corp.
American Home Products Corp. (NYSE:AHP)
License agreement; use of MacroChem's SEPA absorption enhancer for transdermal drug delivery of an American Home Products drug (undisclosed)
ND (includes equity)
MacroChem gets license fees, milestones and royalties; American Home will buy undisclosed amount of MacroChem common stock; American Home will develop and market product (7/98)
Magainin Pharmaceuticals Inc.
Ambalal Sarabhai Enterprises Ltd. (India)
Memorandum of understanding to form a joint venture in India to develop and commercialize certain magainin peptide compounds (including Cytolex [a.k.a. MSI-78] for treating infection in diabetic foot ulcers) as well as other indications
ND
Magainin will license applicable technology to the joint venture and provide technical assistance; Sarabhai will conduct and fund all development and commercialization activities for the joint venture; Magainin and Sarabhai will share profits equally (1/98)
Martek Biosciences Corp.
SmithKline Beecham plc (NYSE:SBH; U.K.)
Research collaboration; use of Martek's reconnaissance probe technology (employs nuclear magnetic resonance spectroscopy) to map binding sites where drugs interact with receptors
ND
SmithKline Beecham licensed technology; further details ND (5/98)
Matrix Pharmaceutical Inc.
Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany)
License agreement on Hoechst Marion Roussel's anticancer agent FMdC (nucleoside analogue that inhibits DNA replication and cell division; completed Phase I trials)
ND
Matrix will pay Hoechst Marion license fee, milestones and royalties; Matrix gets worldwide license, except in Japan (9/98)
Medarex Inc.
Bristol-Myers Squibb Co. (NYSE:BMY)
Research collaboration; use of Medarex's HuMAb-Mouse technology to make high-affinity fully human monoclonal antibodies to multiple antigens for use in Bristol-Myers' oncology drug discovery programs
$20M
Bristol-Myers has option to commercialize antibodies; Medarex gets $20M in R&D funds, license fees and milestones; it also gets royalties (6/98)
Medarex Inc.
Medac GmbH (Germany)
Research collaboration and license agreement; use of Medarex's HuMAb-Mouse technology to make fully human monoclonal antibodies to Medac's CD30 cancer antigen (for treating Hodgkin's lymphoma)
ND
ND (9/98)
Medarex Inc.
Novartis Pharma AG (Switzerland)
License agreement on Medarex's HuMAb-Mouse technology for making fully human monoclonal antibodies
$50M (equity; % ND)
Novartis licensed worldwide rights to use technology company-wide to make antibodies to unlimited number of targets over 10 years; Medarex gets technology access fees, license fees and milestones of $50M; Medarex also gets royalties; Novartis made initial payment of $2M (in equity), and will buy $1M additional equity after 1 year and $3M in equity after 5 years (11/98)
Medarex Inc.
Schering AG (Germany)
Research collaboration and license agreement; use of Medarex's HuMAb-Mouse technology to make fully human monoclonal antibodies to an antigen of Schering's
$9M
Medarex gets R&D payments, license fee and milestones totaling $9M, plus royalties (2/98)
Medical Science Systems Inc.
Glaxo Wellcome plc (NYSE:GLX; U.K.)
Development and license agreement; use of Medical Science's BioFusion technology to develop computer model for new compound screening (computer-based simulation models of complex biological systems)
ND
ND (12/98)
MedImmune Inc.
Pasteur Merieux Connaught (unit of Rhone-Poulenc Group; NYSE:RP; France)
License agreement; use of MedImmune's decorinbinding protein technology to develop 2nd-generation vaccine for prevention of Lyme disease
ND
Pasteur Merieux gets exclusive worldwide rights to technology; MedImmune gets milestones and royalties; further details ND (12/98)
Metra Biosystems Inc.
Beckman Coulter Inc. (NYSE:BEC)
Cross-licensing agreement on patent owned by Beckman Coulter
ND
Beckman Coulter gets rights to Metra's Pyrilinks-D (Dpd) test (urine-based assay for osteoporosis) for use on its automated immunoassay analyzer; Metra gets rights to continue to make, use and sell the Alkphase-B formation marker (for osteoporosis) that it currently markets worldwide (5/98)
Millennium Pharmaceuticals Inc.
Bayer AG (Germany)
Broad, genomics-based drug discovery alliance; use of Millennium's technologies in genetics, genomics, automation and bioinformatics to supply 225 new drug targets to Bayer in areas of cardiovascular disease, cancer, osteoporosis, pain, liver fibrosis, hematology and viral infections (production-oriented approach to move compounds from discovery to clinic)
$465M (14% equity)
Bayer gets access to genomics-based targets for drug development over 5 years; Millennium can develop targets not chosen by Bayer; Millennium will identify and validate targets and will share responsibility with Bayer for making screening assays; Bayer is responsible for high-throughput screening; Millennium gets total of $465M, up to $368.4M of which is guaranteed funding and performance fees for identified targets plus license fees for use of Millennium's genomics technology; the remaining $96.6M is equity investment (4.69M shares or 14% stake); Millennium received $130M ($96.6M for equity, $33.4M upfront license fee) on 11/11/98; companies will share responsibility for qualifying and developing lead compounds; Bayer gets worldwide rights to market small-molecule drugs it chooses to develop from leads; Millennium gets royalties; Millennium retains rights to use information generated to develop therapeutics and diagnostics (9/98)
MitoKor Inc.*
Pfizer Inc. (NYSE:PFE)
Research collaboration; identification of multiple molecular targets and drug candidates (based on mitochondrial dysfunction) for treating neurodegenerative diseases
ND (includes equity)
MitoKor will identify molecular targets that will be screened for drug candidates; companies will work together to identify development candidates; Pfizer will make upfront cash payment and buy equity in MitoKor; MitoKor also gets additional cash and equity on milestones; Pfizer will fund R&D; specific terms ND (11/98)
Molecular Dynamics Inc.
Beckman Coulter Inc. (NYSE:BEC)
Collaboration to develop robotic system to integrate and automate operation of multiple MegaBACE 1000 DNA sequencing units
ND
ND (9/98)
Molecular Dynamics Inc. and Amersham Pharmacia Biotech (Sweden)
American Home Products Corp. (NYSE:AHP)
DNA microarray technology access agreement; collaboration for continued development of new microarray technologies
ND
American Home will provide funding and technical expertise; it gains early access to integrated microarray systems, related support and training programs; microarray technology will be accessed by multiple research centers within American Home, including Genetics Institute, Wyeth-Ayerst and American Cyanamid (4/98)
Molecular Dynamics Inc. and Amersham Pharmacia Biotech (Sweden)
Bristol-Myers Squibb Co. (NYSE:BMY)
DNA microarray technology access agreement; collaboration for continued development of new microarray technologies
ND
Bristol-Myers Squibb will provide funding and technical expertise; it gains early access to integrated microarray systems, related support and training programs (4/98)
Molecular Dynamics Inc. and Amersham Pharmacia Biotech (Sweden)
Hoechst-Ariad Genomics Center (joint venture between Ariad Pharmaceuticals Inc. and Hoechst Marion Roussel Inc.)
DNA microarray technology access agreement; collaboration for continued development of new microarray technologies
ND
Genomics Center will provide funding and technical expertise; it gains early access to integrated microarray systems, related support and training programs (5/98)
Molecular Dynamics Inc. and Amersham Pharmacia Biotech (Sweden)
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc SA; NYSE: RP; France)
DNA microarray technology access agreement; collaboration for continued development of new microarray technologies
ND
Rhone-Poulenc Rorer will provide funding and technical expertise; it gains early access to integrated microarray systems; further details ND (1/98)
Molecular Simulations Inc. (wholly owned subsidiary of Pharmacopeia Inc.)
Bayer AG (Germany)
Bayer joined Molecular Simulations' Polymer 2000 and pharmaceutical development consortia (application of computational chemistry to pharmaceutical development and formulation)
ND
ND (11/98)
Molecular Simulations Inc. (wholly owned subsidiary of Pharmacopeia Inc.)
Glaxo Wellcome plc (NYSE:GLX; U.K.)
Glaxo joined Molecular Simulation's pharmaceutical development consortium (involves application of computational chemistry to pharmaceutical development and formulation)
ND
Scientists at Glaxo's research sites in U.S. and U.K. will participate in consortium; further details ND (5/98)
Molecumetics Ltd. (subsidiary of Tredegar Industries; NYSE:TG)
Bristol-Myers Squibb Co. (NYSE:BMY)
Research collaboration; screening of Molecumetics' MolecuSet compounds for therapeutics for inflammatory and immunological diseases; initial focus on small molecule transcription factor inhibitors
$45M
3-year agreement; Bristol-Myers will screen 150,000 MolecuSet compounds against a number of disease targets; Molecumetics gets research funding and milestones of $45M over 3 years; both firms will work to optimize lead compounds; Molecumetics gets royalties (9/98)
Molecumetics Ltd. (subsidiary of Tredegar Industries; NYSE:TG)
Choongwae Pharma Corp. (South Korea)
License and supply agreement on certain key chemical intermediates for synthesis of compounds using Molecumetics' SMART library technology; also, research collaboration on oral tryptase inhibitors for treating asthma, inflammatory bowel disease and psoriasis
ND
2-year agreement; Choongwae will synthesize and deliver compounds to Molecumetics; it will also perform in vitro and in vivo testing of oral tryptase inhibitors that will be jointly developed; Choongwae gets rights to inhibitors in certain Asian countries; Molecumetics retains rights in all other countries (12/98)
MorphoSys AG* (Germany)
DuPont Pharmaceuticals Co.
Collaboration and licensing agreement; use of MorphoSys' human combinatorial antibody library to generate antibodies for DuPont's drug discovery program
ND
DuPont gets license to antibody library and has option to develop specific antibodies as therapeutics, in vitro or in vivo diagnostics or components of high-throughput screens; MorphoSys gets fees, milestones and royalties (8/98)
Myriad Genetics Inc.
Monsanto Co. (NYSE:MTC)
Research collaboration; use of Myriad's protein interaction database ProNet to understand biochemical pathways of major diseases (ProNet identifies human proteins and links them into specific pathways); initial focus on 2 specific diseases (undisclosed)
$15M
12-15 month collaboration; Myriad gets $15M total, including upfront payment, option payments, license fees and milestones; Myriad also gets royalties; Monsanto gets option to extend research program for additional disease targets; further details ND (11/98)
Myriad Genetics Inc.
Schering AG (Germany)
Research collaboration; use of Myriad's protein interaction database ProNet to understand biochemical pathways of major diseases (ProNet identifies human proteins and links them into specific pathways)
$51M
5-year collaboration; Myriad gets $20M upfront and option to co-promote all new therapeutics in North America, in which case Myriad will get 50% of profits; if Myriad doesn't exercise option, it gets "substantial" royalties; Myriad can exercise copromotion option by paying 50% of drug development costs; total $51M to Myriad also includes license and subscription fees and milestones (10/98)
NanoSystems LLC*
Boehringer Ingelheim GmbH (Germany)
Development, license and supply agreement; use of NanoCrystal technology (improves delivery of poorly water soluble drugs) for undisclosed compound for respiratory delivery
ND
NanoSystems gets upfront license fee, milestone payments and royalties; further terms ND (2/98)
NanoSystems LLC*
Merck & Co. Inc. (NYSE:MRK)
License agreement; use of NanoCrystal technology (to deliver poorly water-soluble drugs) to deliver an undisclosed Merck drug
$30M
NanoSystems gets $30M in precommercialization payments as well as royalties (this is 3rd collaboration between the companies) (8/98)
NaviCyte Inc.*
Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA)
R&D collaboration; development of NaviCyte's computational pharmacokinetics technnology (Pk-Informatics) to identify drug development candidates (enables prediction of pharmacokinetic outcomes in humans)
ND
Parke-Davis is 3rd member of NaviCyte's IDEA consortium (in vitro determination for evaluation of absorption simulation software system); Parke-Davis will make initial and milestone payments to help develop technology; Parke-Davis gets license to software and computational models for use with its compound libraries; it will also fund NaviCyte's evaluation of certain compounds in its in vitro experimental systems (4/98)
Neoprobe Corp.
CIS-US Inc. (subsidiary of CIS-Biointernational; France)
Letter of intent to license CIS' I-125-MIBG drug for use in intraoperative detection of neuroblastoma
ND
CIS will be exclusive supplier of radio-labeled drug to Neoprobe in its licensed territory (not identified) (12/98)
NetGenics Inc.*
American Home Products Corp. (NYSE:AHP)
Collaboration; use of NetGenics' Synergy application framework and software engineering services to integrate and enhance American Home's bioinformatics, genomics and drug discovery programs
ND
4-year agreement; NetGenics will provide enterprise-wide infrastructure for drug discovery within American Home's divisions; financial terms ND (10/98)
Neurobiological Technologies Inc. (OTC Bulletin Board: NTII)
Merz + Co. GmbH & Co. (Germany) and Children's Medical Center Corp.
Research and marketing alliance with Merz and revenue-sharing partnership with Children's Medical on orally active neuroprotective drug Memantine (NMDA receptor antagonist) for treating neuropathic pain, AIDS-related and other dementias and Alzheimer's disease
$2.1M
Children's Medical will terminate its existing license to Neurobiological Technologies on Memantine and grant exclusive rights to Merz instead; in exchange, Neurobiological gets upfront payment of $2.1M from Merz; Neurobiological and Merz will work together to select global marketing partner; companies and Children's Medical will share clinical data; Neurobiological and Children's Medical will share in revenues from product sales for all indications (4/98)
Neurocrine Biosciences Inc.
Medtronic Inc. (NYSE:MDT)
Clinical collaboration; evaluation of Neurocrine's drug NBI-3001 (interleukin-4 Pseudomonas exotoxin fusion protein), delivered directly into brain via Medtronics' implantable infusion pump (SynchroMed) for treating malignant brain tumors
ND
Companies will collaborate to evaluate combined system in the clinic; further details ND (11/98)
NeuroSearch A/S (Denmark) and Meiji Seika Kaisha (Japan)
Pharmacia & Upjohn Inc. (NYSE:PNU; U.K.)
License agreement on anti-anxiety compound NS 2710 (gamma amino butyric acid modulator; now in Phase II trials)
ND
Pharmacia & Upjohn acquired worldwide rights except in Nordic markets, Japan and Asia, where NeuroSearch and Meiji retain rights, respectively; Pharmacia & Upjohn will make initial payment to companies as well as milestones and royalties (7/98)
NeXstar Pharmaceuticals Inc.
Glaxo Wellcome plc (NYSE:GLX; U.K.)
Two-part collaboration: use of NeXstar's Selex drug discovery process (combinatorial chemistry technology that identifies specific inhibitors of targets, called aptamers) for target validation in Glaxo's functional genomics program; development of liposomal formulation of Glaxo's cancer drug candidate Lurtotecan (topoisomerase I inhibitor)
$10M (3.5% equity)
Glaxo gets non-exclusive rights to use NeXstar's Selex process for target validation; NeXstar gets exclusive rights to develop a liposomal formulation of Lurtotecan for treating cancer; Glaxo invested $10M in NeXstar stock (0.96M shares at $10.39 each for a 3.5% stake); Glaxo also gets certain rights to develop aptamers as therapeutics, on which NeXstar gets milestones and royalties; NeXstar gets license to Lurtotecan and Glaxo gets milestones and royalties on marketed products; Glaxo has option to participate in development of this product in exchange for licensing fees and shared development costs (5/98)
Octagen Corp.*
Beaufour Ipsen (France)
Collaboration; use of Octagen's 2nd-generation genetically engineered Factor VIII for therapies for hemophilia
ND (includes equity)
Beaufour made equity investment in Octagen and will pay upfront fee, R & D funding, milestones and royalties; Beaufour gets exclusive worldwide license on any products (10/98)
Oncogene Science Diagnostics Inc. (wholly owned subsidiary of OSI Pharmaceuticals Inc.)
Fujirebio Inc. (Japan)
Collaboration to format cancer diagnostic tests on Fujirebio's automated clinical instrument LumiPulse
ND
4-year agreement; Fujirebio gets non-exclusive license to develop, manufacture and sell several cancer assays in Japan; Oncogene gets licensing fees, R&D funds and royalties (5/98)
Oncor Inc. (AMEX:ONC; indefinite trading halt imposed 10/98)
Becton Dickinson & Co. (NYSE:BD)
Licensing agreement for Oncor's Sunrise Detection System; to be used in conjunction with Becton's Strand Displacement Amplification technology in kits for infectious disease detection
ND
Oncor gets license fees, research funding, milestones and royalties (3/98)
Oncormed Inc. (subsidiary of Gene Logic Inc.)
Merck & Co. Inc. (NYSE:MRK)
Oncormed will provide ras gene testing services for Merck's Phase I clinical trials of an anticancer therapeutic
ND
Oncormed will analyze patient samples (gene characterization and pharmacogenomics); further details ND (5/98)
Oncormed Inc. (subsidiary of Gene Logic Inc.)
Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP)
Oncormed will provide p53 pharmacogenomic services for Schering-Plough's clinical trials of its rAd/p53 cancer gene therapy (to ascertain p53 status of prospective clinical trial subjects)
ND
Oncormed will analyze patient samples (to identify those with missing or defective p53 gene) for Schering-Plough's clinical trials; Oncormed will also provide sequencing and other services (1/98)
OraVax Inc. (OTC Bulletin Board: ORVX)
Pasteur Merieux Connaught (unit of Rhone-Poulenc Group; NYSE:RP; France)
Co-development agreement on vaccine for Dengue fever (mosquitoborn disease caused by any of 4 related viruses); use of OraVax's Chimeri-Vax platform technology, which uses yellow fever 17D vaccine virus as vector forgenes of related viruses
$23.5M
Pasteur Merieux gets exclusive worldwide license; OraVax will develop vaccine through Phase I trials, after which Pasteur Merieux will take over development, manufacturing, marketing and sales; OraVax got initial fee of $1M and also gets R&D funds ($6M over next 12 months), milestones ($16.5M) and royalties; Pasteur Merieux has option to negotiate separate agreement to license OraVax's Japanese encephalitis vaccine worldwide except Korea; in exchange, Pasteur Merieux will fund development and Phase I clinical trial of encephalitis vaccine (12/98)
Orchid Biocomputer Inc.*
Dynal AS (Norway)
License agreement on Dynal's magnetizable bead technologies for use in Orchid's microchemical processing chips
ND (includes equity)
Orchid gets exclusive license to Dynal's bead technologies; Dynal made undisclosed equity investment in Orchid; further details ND (4/98)
Oxford Asymmetry International plc (LSE:OAI; U.K.)
The Ares-Serono Group (Switzerland)
Combinatorial chemistry collaboration; use of Oxford's chemical compound libraries in Ares-Serono's drug lead discovery programs
$4.6M
2-year agreement; Oxford will supply libraries for use in Ares-Serono's Geneva and Boston labs; Oxford gets $4.6M over 2 years and additional payments for each product that is commercialized (prices converted at a rate of #0.59/US$1) (10/98)
Oxford Asymmetry International plc (LSE:OAI; U.K.)
Bayer AG (Germany)
Development of lead discovery libraries of new chemical entities (via Oxford's combinatorial chemistry) as product candidates for Bayer's pharmaceutical, animal health and crop protection businesses
$26M
2-year collaboration; Bayer will screen Oxford's libraries for leads; Oxford gets $14.6M over 2 years plus $11.4M in milestones for each product that completes clinical trials; Oxford also gets royalties (2/98)
Oxford Biomedica plc (AIM:OXB; U.K.)
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc SA; NYSE: RP; France)
Feasibility study on use of Oxford's lentiviral vector systems in Rhone-Poulenc Rorer's functional genomics program (to transfer genes to certain non-dividing tissues)
ND
ND (1/98)
Oxford BioMedica plc (AIM:OXB; U.K.)
RPR Gencell (division of Rhone-Poulenc Rorer Inc.; subsidiary of Rhone-Poulenc SA; NYSE:RP; France)
Collaboration and license agreement on Oxford's Hypoxia Response Element (control element that switches genes on/off in response to oxygen levels) for use in Gencell's cardiovascular gene therapy products
$17.9M (equity; % ND)
RPR Gencell gets exclusive worldwide license; Oxford gets at least $1M in research funds over 1st 2 years; RPR will buy 1.5M shares at $0.34 each (at 100% premium) for $0.51M; RPR will buy more stock ($16.4M total at 10% premium) to pay for milestones; Oxford will develop screens for small molecule therapeutics; Oxford also gets royalties (prices converted at a rate of #0.59/US$1) (12/98)
Oxford Glyco-Sciences plc (U.K.)
Pfizer Inc. (NYSE:PFE)
Collaborative research agreement to apply Oxford's proteomics technology to identify disease-specific proteins as diagnostics, clinical markers of disease and drug development targets; 1st focus is Alzheimer's disease
$50M (1.5% equity)
2-year research program and 5-year clinical collaboration; Pfizer bought 0.54M shares for $2.5M in a private placement concurrent with Oxford's 4/98 IPO (same price per share); Pfizer will fund research for 2 years; Oxford also gets milestones and royalties; total value of deal up to $50M; companies will jointly own intellectual property; Oxford has exclusive rights to commercialize diagnostic markers; once analysis of Pfizer's Alzheimer's samples is complete, it has option to select a 2nd disease indication (4/98)
Oxford Molecular Group plc (U.K.)
The Procter & Gamble Co. (NYSE:PG)
Use of Oxford Molecular's RS3 Discovery and RS3 Discovery High Throughput Screening research information management software in Procter & Gamble's discovery research programs
ND
ND (5/98)
Pangea Systems Inc.*
Bristol-Myers Squibb Co. (NYSE:BMY)
License agreement on Pangea's computational algorithms for clustering and alignment of expressed sequence tags within large databases; for use in Bristol-Myer's genomics research
ND
ND (9/98)
Pangea Systems Inc.*
Eli Lilly and Co. (NYSE:LLY)
License agreement; use of Pangea's bioinformatics software in Lilly's genomics and target validation programs
ND
ND (7/98)
Pangea Systems Inc.*
Hoechst-Ariad Genomics Center (joint venture between Ariad Pharmaceuticals Inc. and Hoechst Marion Roussel Inc.)
License agreement on Pangea's computational algorithms for clustering and alignment of expressed sequence tags within large databases
ND
ND (8/98)
Pangea Systems Inc.*
Monsanto Co. (NYSE:MTC)
License agreement on Pangea's computational algorithms for clustering and alignment of expressed sequence tags within large databases; for use in Monsanto's life sciences genomics research (agricultural and pharmaceutical)
ND
ND (11/98)
PathoGenesis Corp.
Bristol-Myers Squibb Co. (NYSE:BMY)
License agreement on Bristol-Myers' antibiotic drug candidate (PA-1806; monobactam) for treating various bacteria that cause chronic lung infections; to be delivered via inhalation
$4M
Pathogenesis gets exclusive worldwide license in exchange for initial payment of $4M; it will also pay milestones and royalties to Bristol-Myers (10/98)
Peptide Therapeutics Group plc (U.K.)
Pasteur Merieux-OraVax (joint venture between Ora-Vax Inc. and Pasteur Merieux Connaught [unit of Rhone-Poulenc SA; France])
Collaborative agreement to develop vaccines for treating Helicobacter pylori infection by incorporating Pasteur Merieux-OraVax's H. pylori antigens into Peptide Therapeutics' Salmonella typhi-based oral vaccine delivery system
ND
Pasteur Merieux-OraVax gets worldwide exclusive option to use Peptide Therapeutics' vaccine delivery technology; if it exercises option, Peptide Therapeutics gets license fees, upfront and milestone payments as well as royalties; Peptide Therapeutics retains rights to license delivery system to other parties for use in other vaccines (4/98)
Pharmaceutical Product Development Inc.
Eli Lilly and Co. (NYSE:LLY)
Licensing of certain of Lilly's genitourinary compounds to develop as treatments for bladder dysfunction and sexual dysfunction
ND
Pharmaceutical Product gets worldwide license to compounds; Lilly gets licensing fees and royalties; Lilly gets 1st option to relicense compounds in future (5/98)
Pharmacopeia Inc.
Schering AG (Germany)
Multitarget screening agreement; use of Pharmacopeia's multimillion small-compound library to screen multiple targets chosen by Schering
$64M
Chemical optimization of active compounds identified via highthroughput screening may be performed by either company; Pharmacopeia gets $64M in R&D payments and milestones, plus royalties (10/98)
Pharmacopeia Inc.
Schering-Plough Corp. (NYSE:SGP)
Research collaboration; use of Pharmacopeia's combinatorial libraries for discovering and optimizing lead drug candidates against targets chosen by Schering-Plough
$60M
This is 2nd new collaboration between the parties; Pharmacopeia gets $60M in research funds over 5 years; it also gets milestones and royalties; Pharmacopeia will create combinatorial libraries for use by Schering-Plough; Pharmacopeia will also design an entire discovery program around Schering-Plough's targets; further details ND (11/98)
Phylos Inc.*
Hoechst Research and Technology Deutschland GmbH & Co. KG (HR&T; wholly owned subsidiary of Hoechst AG; Germany)
Collaboration to jointly develop applications of Phylos' directed protein evolution technology (in vitro formation of mRNA-protein fusions allows repeated rounds of mutation and selection of peptides or proteins)
$27M (equity; % ND)
5-year collaboration; companies will jointly develop and have coexclusive rights to technology; HR&T will take undisclosed equity stake in Phylos; further details ND (4/98)
Phytera Inc.*
Eli Lilly and Co. (NYSE:LLY)
Research collaboration; use of Phytera's antifungal screens (genomics-based) plus its natural product extracts (plant cell cultures and marine microbial libraries) to discover products for diagnosis, treatment and prevention of infectious fungal diseases in humans and animals
ND (includes equity)
Lilly will provide compounds for screening in Phytera's systems; Lilly responsible for profiling, lead optimization, development and commercialization; Phytera gets upfront equity investment, research funds, milestones and royalties; Lilly gets worldwide rights to products (7/98)
Phytopharm plc (U.K.)
Pfizer Inc. (NYSE:PFE)
Collaboration to develop appetite suppressant based on P57 (product derived from extract of South African plant)
$39M
Pfizer will contribute $7M to Phase I trial (about to begin) and $32M in license fees and milestones; Pfizer gets exclusive worldwide license to drug (8/98)
PowderJect Pharmaceuticals plc (U.K.)
Glaxo Wellcome plc (NYSE:GLX; U.K.)
Collaboration, development, license and option agreement on DNA vaccines using PowderJect technology (includes prophylactic hepatitis B virus (HBV) DNA vaccine, HBV and HIV DNA vaccines, DNA vaccines for 2 infectious diseases and others); technology based on DNA-coated gold particles delivered via needleless injection (prophylactic HBV vaccine in clinical trials)
$321M (7.7% equity)
Glaxo gets exclusive worldwide rights to use PowderJect technology to commercialize prophylactic HBV vaccine and options on others; Glaxo will take over development of prophylactic HBV vaccine, for which it will pay $4M license fee; Glaxo will also buy $20M of equity (4.9M shares for a 7.71% stake) and pay another $297M in milestones, research funding and license fees as it exercises its options on the other vaccines; Glaxo will be responsible for all vaccine development and commercialization; PowderJect gets royalties; PowderJect will manufacture and supply its device; 5-year agreement subject to antitrust considerations (3/98)
PPD Discovery (subsidiary of Pharmaceutical Product Development Inc.)
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc SA; NYSE:RP; France)
Functional genomics collaboration; use of PPD's GSX System (isolates functional inhibitors, or genetic suppressor elements, of any gene) to identify human gene targets in oncology, inflammation, cardiovascular diseases and central nervous system disorders
$30M
4-year agreement; Rhone-Poulenc will fund R&D ; Rhone-Poulenc gets worldwide rights to therapeutics developed from gene targets; PPD gets worldwide rights to diagnostic uses, including pharmacogenomics; PPD also gets rights to develop therapeutics for targets not chosen by Rhone-Poulenc, on which Rhone-Poulenc has 1st option on license; Rhone-Poulenc gets non-exclusive license to GSX technology; PPD and Rhone-Poulenc will pay each other milestones and royalties on each other's products; PPD gets $20M-$30M if targets in 2 of 4 therapeutic areas are identified and validated (12/98)
Progenics Pharmaceuticals Inc.
Roche Discovery Welwyn (U.K.; member of The Roche Group; Switzerland)
Collaboration on orally active drugs that target HIV co-receptors CCR5 and CD4 (required for fusion and infection of immune cells)
ND
Roche gets exclusive worldwide license to Progenics' HIV coreceptor technology; Progenics gets upfront and milestone payments, research funding for 3 years and royalties (1/98)
Protein Design Labs Inc.
Eli Lilly and Co. (NYSE:LLY)
Collaborative agreement on antibiotics for treating certain bacterial infections, including those caused by antibiotic-resistant strains; use of highthroughput screens and combinatorial chemistry to identify bacterial genes that are differentially expressed during infection
$15M
Protein Design got $3M in initial fee and gets annual research funding of $2.4M for 5 years; Protein Design also gets milestones and royalties; Lilly gets exclusive worldwide rights to gene targets and human pharmaceutical and related diagnostic products directed to 7 specific genera of bacteria; Protein Design retains rights to targets and compounds related to other bacteria, viruses and fungi; parties will negotiate co-promotion rights in U.S. and Canada (1/98)
Proteome Sciences plc (AIM:PRM; U.K.)
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc SA; NYSE:RP; France)
Research collaboration; use of proteomics to identify differentially regulated proteins in failing myocardium (cardiovascular disease)
ND
2-year agreement; Rhone-Poulenc Rorer will fund research and retains all rights to therapeutic uses for heart disease and heart failure; Proteome retains all rights to diagnostics; Proteome and Harefield Hospital (U.K.) get royalties for therapeutics (9/98)
Proteomix Inc. (subsidiary of NovaDx International Inc.; VSE: NVN; Canada)
Bayer Corp. (unit of Bayer AG; Germany)
Research collaboration on series of osteoclast genes as drug targets for metabolic bone disease
$3M
Bayer gets access to genes and will pay $3M in milestones; further details ND (9/98)
Proteomix Inc. (subsidiary of NovaDx International Inc.; VSE: NVN; Canada)
Orincon Technologies Inc.
Option on license to Orincon's 2D-electrophoresis image analysis software for use in proteomics research
ND
ND (7/98)
QLT PhotoTherapeutics Inc. (Canada)
C.R. Bard Inc.
Alliance to combine QLT's photodynamic therapy with Bard's catheter-based intra-vascular delivery systems as therapy for reducing arterial restenosis (localized drug delivery)
ND
Bard will fund product development and clinical research; Bard gets exclusive worldwide marketing rights; QLT gets royalties; QLT retains option to co-fund R&D at later date in exchange for increased share of revenues (4/98)
RiboGene Inc.
Dainippon Pharmaceutical Co. Ltd. (Japan)
Collaboration on antibacterial compounds that inhibit or interfere with protein translation in pathogenic bacteria (will use 2 of Ribo-Gene's principal bacterial targets)
$8M (equity; % ND)
Dainippon gets exclusive worldwide rights to develop and market products; RiboGene gets $2M annually for 3 years to fund research; Dainippon will also buy $2M in RiboGene equity; Ribo-Gene gets milestone payments for each compound, as well as royalties; RiboGene has right to co-promote products in Europe and U.S.; RiboGene retains rights to its other bacterial targets (1/98)
RiboGene Inc.
Roberts Pharmaceutical Corp. (AMEX:RPC)
Option and license agreement on Ribo-Gene's Emitasol (metoclopramide; intranasal drug for treating delayed onset nausea and vomiting in cancer chemotherapy patients)
$27M (equity; %ND)
Roberts bought $10M in equity (1.4M shares of Series A nonvoting convertible preferred stock at $7/share); Roberts will conduct all product development; after FDA approval, Roberts has 90-day exclusive option to license marketing rights in North America; if it exercises option, RiboGene gets $10M; RiboGene also gets royalties; RiboGene will provide $7M in development funds through submission of NDA (7/98)
Ribozyme Pharmaceuticals Inc.
Glaxo Wellcome plc (NYSE:GLX; U.K.)
Genetic target validation and discovery agreement via Ribozyme's technology and GeneBloc molecules (inhibit gene expression)
ND
Glaxo will designate target genes and Ribozyme will design, synthesize and deliver GeneBloc reagents; financial terms ND (7/98)
Ribozyme Pharmaceuticals Inc.
Roche Bioscience (division of Roche Holding Ltd.; Switzerland)
Functional genomics collaboration; use of combinatorial ribozyme library to identify genetic therapeutic targets (identifies genes by phenotype without prior knowledge of sequence)
ND
Roche Bioscience will provide in vivo models for undisclosed disease pathways; Roche Bioscience will conduct clinical development and commercialization; Ribozyme will design, synthesize and deliver ribozymes; Roche Bioscience has rights to small-molecule and ribozyme-based therapeutics against validated targets; Ribozyme has certain limited rights to ribozyme-based therapeutics; Roche will fund R&D, pay milestones and royalties (5/98)
Sangamo BioSciences Inc.*
Bayer Corp. (unit of Bayer AG; Germany)
Research collaboration; use of Sangamo's Universal GeneTools (rationally designed zinc finger DNA recognition proteins that selectively recognize and regulate any target gene or DNA sequence) to identify and validate gene targets for drug discovery
ND
Bayer gets specific GeneTools to evaluate; companies may enter into broader agreement; details ND (12/98)
Sangamo BioSciences Inc.*
Pfizer Inc. (NYSE:PFE)
Research collaboration; use of Sangamo's Universal GeneTools (rationally designed zinc finger DNA recognition proteins that selectively recognize and regulate any target gene or DNA sequence) to validate gene targets for drug discovery
ND
Pfizer will provide funding in exchange for use of Sangamo's technology; financial terms ND (9/98)
Sangamo BioSciences Inc.*
SmithKline Beecham plc (NYSE:SBH; U.K.)
Research collaboration; use of Sangamo's Universal GeneTools (rationally designed zinc finger DNA recognition proteins that selectively recognize and regulate any target gene or DNA sequence) in Smith-Kline's transgenic mouse systems for validating gene targets
ND
ND (10/98)
Sangamo BioSciences Inc.*
Zeneca Pharmaceuticals (unit of Zeneca Group plc; NYSE:ZEN; U.K.)
Research collaboration; use of Sangamo's Universal GeneTools (rationally designed zinc finger DNA recognition proteins that selectively recognize and regulate any target gene or DNA sequence) to identify and validate gene targets for drug discovery
ND
Zeneca will provide funding to Sangamo in exchange for use of technology; further details ND (11/98)
Seattle Genetics Inc.*
Bristol-Myers Squibb Co. (NYSE:BMY)
Licensing of Bristol-Myer's monoclonal antibody-based cancer targeting program (includes immunotoxins, antibody-based drug conjugates, others)
ND
Seattle Genetics was founded by 2 former Bristol-Myers scientists; Seattle Genetics licensed the entire program and paid Bristol-Myers a one-time licensing fee; Bristol-Myers gets royalties; other details ND (4/98)
Sepracor Inc.
Eli Lilly and Co. (NYSE:LLY)
License agreement on Sepracor's single-isomer version of fluoxetine (active ingredient in Prozac) for treating depression (currently in U.S. Phase I trials)
$90M
Lilly gets exclusive worldwide license; Sepracor gets upfront milestone payment and license fee of $20M total, plus $70M in additional milestones and royalties; Lilly gets rights for all uses and indications; Lilly responsible for all subsequent product development, regulatory submissions, manufacturing, marketing and sales (12/98)
Sepracor Inc.
Janssen Pharmaceutica NV (Belgium; unit of Johnson & Johnson; NYSE: JNJ)
Collaboration and license agreement on 3rd-generation nonsedating antihistamine norastemizole (for treating seasonal allergic rhinitis)
ND
Companies will jointly fund product development; Janssen has option to acquire certain rights in U.S. and elsewhere; if exercised, companies will share equally costs and profits of further development; Sepracor retains rights to co-promote in U.S.; Janssen has rights elsewhere (2/98)
Sepracor Inc.
Janssen Pharmaceutica NV (Belgium; unit of Johnson & Johnson; NYSE: JNJ)
License agreement on (+) norcisapride (isomer of active metabolite of Janssen's marketed drug Propulsid for treating heartburn due to gastroesophageal reflux)
ND
Janssen gets exclusive license to all of Sepracor's worldwide rights to norcisapride enantiomers; Sepracor has option to copromote product in pediatric market (7/98)
Sequenom*
Bruker-Franzen Analytik GmbH (Germany)
Collaborative agreement to develop highspeed mass spectrometer dedicated to processing Sequenom's Spectro-Chips for DNA analysis (functional microarrays)
ND
Bruker-Franzen will upgrade the hardware and software interfaces of its instruments to enable them to process Sequenom's Spectro-Chips exclusively (1/98)
Sheffield Pharmaceuticals Inc.
Zambon Group SpA (Italy)
Strategic alliance to develop 4 drugs for treating respiratory disease using Sheffield's Metered Solution Inhaler (MSI) (drugs include albuterol, beclomethasone, ipratropium and cromolyn)
$25M (13% equity)
Zambon made $2.15M equity investment in Sheffield (including the $0.65M it paid as an option fee in 4/98); Sheffield gets $2M interest-free loan as advance on future milestones; Zambon will assume all development costs (estimated at $20M) for 4 drugs; Sheffield gets milestones on NDA approval of each of 4 drugs and for 1st European product licenses for each drug; Sheffield gets royalties on Zambon's sales and copromotion rights in U.S.; Sheffield retains rights to non-respiratory disease applications of MSI system (option agreement 4/98; final agreement 6/98)
Signal Pharmaceuticals Inc.*
DuPont Merck Pharmaceutical Co. (partnership between the DuPont Co. [NYSE:DD] and Merck & Co. Inc. [NYSE:MRK])
Collaboration on drugs for hepatitis C virus (HCV) and HIV infection; use of Signal's high-throughput screening assays to identify virus-specific generegulating targets
$25M (equity; % ND)
3-year collaboration; DuPont will provide research funding, upfront and milestone payments; DuPont will buy equity stake in Signal's IPO; Signal will screen for and identify leads; DuPont will optimize leads, and develop and market products; Signal gets royalties (1/98)
Signal Pharmaceuticals Inc.*
Nippon Kayaku Co. Ltd. (Japan)
Collaboration to develop Nippon's smallmolecule nerve growth factor mimetic as a drug for treating peripheral neuropathies; use of Signal's human neuronal cell lines to optimize compound and characterize its mode of action
ND
Nippon will provide research funding to Signal for 1st 2 years and will continue to conduct animal pharmacology studies; Signal will optimize compound prior to clinical trials via combinatorial chemistry and neuronal cell lines; companies will codevelop product and share marketing rights worldwide except Japan (2/98)
SkyePharma plc (U.K.)
Novartis Pharma AG (Switzerland)
Collaboration; use of Skye-Pharma's multidose dry powder inhaler device to make new formulation of long-acting bronchodilator Foradil (beta-agonist for treating asthma)
$10.1M (2% equity)
Companies will jointly develop new formulation; SkyePharma responsible for finished formulation, including manufacturing; Novartis will pay technology access fee, development costs and milestones; Novartis also bought $10.1M in equity (8.6M shares at $1.174 each; at 13% premium) for 2% stake; Novartis gets exclusive worldwide rights; Skye-Pharma gets royalties (prices converted at rate of #0.59/US$1) (11/98)
Soane BioSciences Inc.*
The Perkin-Elmer Corp. (NYSE:PKN)
Collaboration to develop automated and integrated genetic analysis systems based on Soane's microfluidics technology (electric fields move reagents through micro-capillaries on chips)
ND (includes equity)
Perkin-Elmer made undisclosed equity investment in Soane; both companies will invest in joint research and product development; Perkin-Elmer gets exclusive worldwide license to commercialize products; Soane will manufacture and supply the microfluidic chips (5/98)
Sparta Pharmaceuticals Inc.
Schering-Plough Corp. (NYSE:SGP)
Licensing agreement on Sparta's Spartaject drug delivery system (for injection of poorly water soluble or insoluble compounds) for use with Schering's oral anti-cancer agent Temodal (in development for treating recurrent malignant melanoma)
ND
Schering-Plough paid Sparta upfront license fee; Sparta also gets milestones and royalties (4/98)
Structural Bioinformatics Inc.*
Yamanouchi Pharmaceutical Co. Ltd. (Japan)
Drug discovery collaboration on undisclosed target of Yamanouchi's; use of Structural Bioinformatics' computational molecular modeling and virtual screening technology to identify small-molecule drug candidates
ND
ND (4/98)
Sugen Inc.
Taiho Pharmaceutical Ltd. (Japan)
Alliance to develop Sugen's angiogenesis inhibitors (including SU5416, currently in Phase I/II trials) for preventing and treating cancer
$70M
Taiho will help fund product development; Taiho gets marketing rights in Japan; Sugen retains rights in rest of world; Sugen gets upfront payments, research funds and milestones totaling $70M; Sugen will manufacture and supply product to Taiho for sale in Japan (7/98)
Supratek Pharma Inc.* (Canada)
RPR Gencell (division of Rhone-Poulenc Rorer Inc.; subsidiary of Rhone-Poulenc SA; NYSE:RP; France)
Collaboration; use of Supratek's biotransport carrier technology (gene delivery system) for certain of RPR Gencell's cardiovascular projects
ND
RPR Gencell will fund feasibility study of Supratek's system and gets option on exclusive license (11/98)
Synaptic Pharmaceutical Corp.
Glaxo Wellcome plc (NYSE:GLX; U.K.)
Licensing agreement for certain of Synaptic's alpha adrenergic receptor patents and functional use patents for treating benign prostatic hyperplasia
$2M
Synaptic had already licensed these rights to Merck & Co. under an 11/93 agreement; thus Merck had to approve the transaction with Glaxo; Glaxo gets non-exclusive license to receptor patents; Synaptic got $2M upfront and will get additional payment if Merck exercises option on non-exclusive license to functional use patents (option expires 5/22/99); Synaptic gets milestones under certain conditions and royalties (3/98)
Synaptic Pharmaceutical Corp.
Grunethal GmbH (Germany)
Cooperative agreement to develop drugs for treating pain via Synaptic's cloned human receptor-targeted drug design technology and Grunethal's pain model systems; initial focus on alpha-2 adrenergic receptors
ND
Grunethal will conduct preclinical and clinical studies; Synaptic retains manufacturing and marketing rights in U.S., Canada and Mexico; Grunethal has those rights in Europe and Central and South America; companies will share rights elsewhere; companies are each responsible for own expenses during research phase and will share equally all costs through Phase II trials (1/98)
Synt:em* (France)
Laboratoires Servier (France)
Research collaboration on vectorization of anticancer molecules using Synt:em's Pep:trans technology (enables creation of peptidic vectors able to cross cell membranes, thus internalizing drugs into cancer cells)
ND
Servier will develop and market products; Synt:em gets milestone payments; further details ND (2/98)
Targeted Genetics Corp.
Medeva plc (NYSE:MDV; U.K.)
Research collaboration on Targeted Genetics' tgAAV-CF gene therapy product for treating cystic fibrosis (uses adeno-associated virus to deliver normal CFTR gene)
$54M (equity; % ND)
Targeted Genetics gets $54M, comprised of $5M license fees, $19M in milestones, $3M in equity investment, $2M loan and $15M research funding over 3 years; it also has option under certain conditions to get another loan of $10M for building manufacturing facility for product; Medeva will fund clinical and regulatory costs; Targeted Genetics will manage U.S. clinical trials through Phase I and may manage Phase IIs; Medeva will manage all other trials; Medeva will buy product from Targeted Genetics under long-term supply agreement (11/98)
TerraGen Diversity Inc.* (Canada)
Schering-Plough Research Institute (unit of Schering-Plough Corp.; NYSE:SGP)
Collaboration; use of TerraGen's combinatorial biosynthesis technology to discover anti-infective compounds derived from unculturable, environmental microorganisms
ND
TerraGen will generate and screen libraries of traditionally inaccessible microbial compounds; TerraGen gets annual R&D funds, milestones and royalties; Schering-Plough responsible for product development; TerraGen retains rights to its libraries; parties will jointly patent chemical structures of lead compounds (12/98)
Therapeutic Antibodies Inc.
G.D. Searle & Co. (division of Monsanto Co.; NYSE: MTC)
Research collaboration; development of ovine polyclonal antibody to undisclosed therapeutic target of Searle's
$8M
Therapeutic Antibodies will develop, manufacture and register product; Searle will pay $8M to fund R&D and buy product supplies ($1M paid on signing); Searle gets worldwide marketing rights; companies will share revenues (5/98)
TheraTech Inc.
Astra AB (Sweden)
Use of TheraTech's oral transmucosal delivery technology to develop undisclosed peptide as treatment for pain (peptide being developed by Astra and BioChem Pharma Inc.)
ND
Astra will market product worldwide; TheraTech gets R&D payments, licensing fees and royalties (5/98)
Therion Biologics Corp.*
Pasteur Merieux Connaught (Canada; member of the Rhone-Poulenc Group) and its affiliate Virogenetics Corp.*
Collaboration to develop live recombinant pox virus vector-based therapeutic vaccines for colorectal and lung cancer and melanoma
$25M (equity; % ND)
Cross-licensing agreement; Pasteur gets exclusive rights to certain of Therion's therapeutic cancer vaccines; Therion gets access to certain of Pasteur's pox virus vector technologies; Pasteur gets exclusive worldwide rights to Therion's therapeutic melanoma vaccines and carcinoembryonic antigen (CEA)-based therapeutic vaccines; Therion gets $25M in milestones; Pasteur made initial equity investment in Therion (1/98)
Transgene SA (France)
Schering-Plough Corp. (NYSE:SGP)
Research collaboration and license agreement; use of Transgene's adenoviral gene delivery systems with Schering-Plough's p53 tumor suppressor gene (and several other genes) to develop gene therapy products
$88M
5-year collaboration; Schering-Plough gets rights to existing and future adenoviral gene technology for use with p53 gene; Schering-Plough has option to license Transgene's adenoviral systems for up to 5 additional genes; Transgene gets $8M in initial license fees; if Schering-Plough exercises options for all 6 genes, Transgene gets $88M (licensing fees, research funding, milestones); Transgene also gets royalties (2/98)
Trega Biosciences Inc.
Novartis Pharma AG (Switzerland)
Research collaboration and license agreement on orally active small molecules for treating diseases mediated by melanocortin receptor pathway (associated with MC-4 receptor), including Type II diabetes, obesity and Syndrome X
$39M
Trega will screen its combinatorial chemistry libraries and confirm activity and function for drug candidates; companies will collaborate to optimize candidates and test preclinically; Novartis will conduct clinical development and commercialize products worldwide; Trega has option to get an equity investment from Novartis; Trega gets payments for past research, current R&D funding and milestones worth up to $39M for the 1st product (up to $19M in guaranteed funding); Trega also gets royalties; Trega will get additional milestones and royalties for subsequent products (deal could be worth $50M-$75M in all) (5/98)
Trega Biosciences Inc.
Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA)
Research collaboration on Trega's Chem.Folio (combinatorial chemistry libraries) for use in Parke-Davis' drug discovery programs
ND
This new agreement supercedes the 5/97 agreement between the companies; Parke-Davis will buy $1.5M of Trega's combinatorial libraries on non-exclusive basis; as a result, it will not buy Trega stock (per the 1997 agreement); further details ND (12/98)
Triangle Pharmaceuticals Inc.
Bukwang Pharmaceuticals Ind. Co. Ltd. (South Korea)
Licensing of L-FMAU (a pyrimidine nucleoside analogue intended for treating hepatitis B virus infection)
$6M
Triangle licensed rights to product for all human antiviral applications worldwide except Korea; Bukwang gets upfront fee of $6M, milestone payments and royalties (2/98)
Tripos Inc.
Boehringer Ingelheim R&D (Austria; unit of Boehringer Ingelheim GmbH; Germany)
Software consulting and custom software development agreement; use of Tripos' Web-based scientific information services
ND
Boehringer Ingelheim will use customized software to access biological screening, chemical and genomic data (3/98)
Tularik Inc.*
Japan Tobacco Inc. (Japan)
Research collaboration; development of smallmolecule therapeutics to regulate orphan nuclear receptors (which are transcription regulators)
ND
3-year agreement; companies will share development and commercialization costs and profits worldwide; Tularik gets exclusive rights in U.S. and Canada; Japan Tobacco gets exclusive rights in Japan and Korea (9/98)
Tularik Inc.*
Knoll AG (Germany)
Collaboration on drugs that act on regulatory targets in energy metabolism pathways, for treating obesity
ND
3-year agreement; Tularik gets R&D funds, milestones and royalties; Knoll responsible for all product development (preclinical through regulatory clearance); Knoll gets worldwide marketing rights, except in Asia; Knoll has option of expanding collaboration to include additional targets in obesity (12/98)
UroGen Corp. (OTC Bulletin Board:UROG)
Baxter Healthcare Corp. (subsidiary of Baxter International Inc.; NYSE:BAX)
Joint collaboration on gene therapies for blood disorders; use of Baxter's recombinant adenoviral vectors for gene transfer and Uro-Gen's tumor sensitization and related technologies
$25M (>19% equity)
UroGen bought exclusive rights to Baxter's gene transfer technology with 5,444 shares of Series A convertible preferred stock; UroGen may also buy rights to other gene therapy technologies by paying 1.76M shares of common stock and 324 shares of Series A convertible preferred stock; Baxter will pay $22M-$25M to fund joint development of gene therapies and gets worldwide marketing rights (7/98)
Vanguard Medica Group plc (U.K.)
Stiefel Laboratories Inc.*
R&D collaboration on VML 262 as a topical treatment for psoriasis (compound was originally isolated from marigolds and is now chemically synthesized; Phase II trials initiated 2/98)
$8M
Vanguard responsible for clinical development through Phase II, at which point Steifel will take over clinical trials (which it will fund); Steifel gets product rights in European Union and Latin America; Steifel will reimburse some of Vanguard's preclinical development costs; Vanguard will get $8M in milestones over 4-5 years, as well as royalties (3/98)
Vertex Pharmaceuticals Inc.
Schering AG (Germany)
Strategic alliance on development of orally active neurophilin compounds to promote neural regeneration in treating neurological diseases
$88M
5-year agreement; companies will co-manage R&D ; Schering will provide $28M in upfront and research support over 5 years plus $60M in milestones; Vertex retains manufacturing rights in North America, where companies will share marketing expenses and profits; Schering has right to manufacture products in Europe, the Middle East and Africa, where Vertex gets royalties; Vertex has option to manufacture bulk drug substance for other markets (8/98)
Visible Genetics Inc. (Canada)
Organon Teknika (subsidiary of Akzo Nobel NV; the Netherlands)
License agreement on Organon's Boom technology (method for extracting RNA and DNA from plasma and RNA from other bodily fluids)
ND
Visible Genetics gets right to sell nucleic acid extraction kits based on Boom technology (10/98)
Xenogen Corp.*
F. Hoffmann-La Roche Ltd. (Switzerland)
License agreement; evaluation of Xenogen's biophotonic imaging technology and up to 4 strains of bacteria genetically engineered with reporter genes that code for light-emitting proteins
ND
Roche will evaluate technology in its preclinical drug development program; further details ND (9/98)
Xenova Group plc (U.K.) and its subsidiary MetaXen LLC
Eli Lilly and Co. (NYSE:LLY)
R&D collaboration on small-molecule inhibitors of plasminogen activator inhibitor (PAI-1) from Xenova's natural products library as anti-thrombotic drugs for chronic use
$35M
Xenova and MetaXen will get $35M in license fees, research funding and milestones, as well as royalties; Lilly gets exclusive worldwide rights to PAI-1 inhibitors and related technology for use in cardiovascular medicine; Meta-Xen will conduct preclinical work; Lilly responsible for clinical trials and product registrations as well as marketing (2/98)
See subscription options